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Introduction
Complex Regional Pain Syndrome type 1 (CRPS1) is a disease of 
the extremity that usually occurs as a complication after surgery 
or trauma, although spontaneous occurrence has also been 
described [1]. The clinical features include pain/sensory abnor-
malities, vasomotor dysfunction, edema/sudomotor dysfunction, 
and motor/trophic changes [2]. The diagnosis of CRPS is based 
on findings during the history and physical examination. Several 
diagnostic criteria sets have been developed, and the most used 
are the Veldman criteria [3], the IASP criteria (the International 
Association for the Study of Pain) [4], and the Bruehl criteria 
[5, 6]. There is a distinction between CRPS types 1 and 2. Type 
1 occurs without any peripheral nerve lesion, whereas in type 2 
there is definite peripheral nerve damage.
In the Netherlands, the incidence of CRPS is estimated to be 
approximately 26.2 per 100,000 person years, with a median age 
of onset of 52.7 years. CRPS occurs more often in females than 
in males, with a ratio of approximately 3.4:1. The upper extremity 
is more often affected than the lower extremity, and the right and 
the left sides of the body are affected with the same frequency. A 
fracture is the most common precipitating event (44%) for CRPS, 
followed by a contusion/sprain in 17% of the population [7].
There is a long-standing belief described in the literature that 
untreated CRPS develops through a sequence of distinct stages, 
each stage characterized by a different pattern of signs and 
symptoms [3, 8-10]. While the clinical descriptions of these 
hypothesized stages have differed somewhat in the details among 
authors, most conform to the general description by Bonica (1990). 
Although only limited empirical tests of this hypothesized staging 
of CRPS have been reported, this concept has been frequently 
accepted as a fact in the CRPS literature (e.g., [8, 10]). 
The early, acute stage of CRPS (Stage I) is believed to be 
characterized by pain/sensory abnormalities (e.g., hyperalgesia, 
allodynia), signs of vasomotor dysfunction that affect skin color, 
often increased temperature of the skin, prominent edema, and 
sudomotor disturbance. Stage II (dystrophic stage) is charac-
terized by more marked pain/sensory dysfunction, continued 
evidence of vasomotor dysfunction and sudomotor dysfunction, 
with development of significant motor/trophic changes. Stage III 
(atrophic stage) is characterized by decreased pain/sensory distur-
bance, continued vasomotor disturbance often with a decreased 
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temperature of the skin, and markedly increased motor/trophic 
changes that become irreversible [2, 11, 12].  
Because the prominent signs and symptoms seen in the early 
stage of CRPS resemble the characteristic signs of inflammation, 
such as pain, increased skin temperature and skin color changes, 
swelling of the extremity, and loss of function, the question that 
arises is whether or not an inflammatory process is involved in 
CRPS. An inflammatory process is substantiated by the gener-
ation of mediators of inflammation at the site of the injury, a 
specific antagonist or synthesis inhibitor that shows a beneficial 
effect, and a worsening of the clinical manifestations by injection 
of the mediator(s). Figure 1 depicts some candidate mediators for 
one or more signs and symptoms seen in CRPS. Their common 
functions are described below.
Neuropeptides
Bradykinin is an endogenous peptide produced in plasma and 
peripheral tissue that can activate two different receptors (B1 and 
B2). The B2 receptors are found both peripherally and centrally 
and are responsible for the physiological response of brady-
kinin. However, B1 receptors can be activated under pathological 
conditions or by trauma, and also by endotoxins and cytokines. 
Bradykinin increases pain sensitivity via a glutamate-dependent 
activation of the N-methyl-aspartate (NMDA) receptor [13]. 
Bradykinin can provoke substance P (SP) release, and both can 
trigger mast cell secretion [14]. They may also be involved in the 
development of inflammatory responses. The mast cells release 
vasodilatory, nociceptive, and pro-inflammatory mediators, thus 
causing an allergic reaction [15]. 
The sensory system stores SP and calcitonin gene-related peptide 
(CGRP). SP is a co-transmitter in primary afferent nerve fibers, 
involved in nociception in both the peripheral nervous system and 
the central nervous system. It is responsible for neurogenic inflam-
mation, including local cell response, skin reddening, edema 
formation, and mechanical hyperalgesia. It is suggested that SP 
acts by release of inflammatory mediators, such as cytokines, 
oxygen radicals, arachidonic acid, and histamine. It also enhances 
lymphocyte proliferation and immunoglobulin production [16, 
17]. By activation of the NK1 receptor, SP increases the production 
of prostaglandin E2 (PGE2) and evokes thermal hyperalgesia 
[14]. SP mediates mainly plasma leakage (extravasation), and its 
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levels are increased during stress and inflammation [15], whereas 
CGRP is the major vasodilator neurotransmitter in the coronary, 
cutaneous, and cerebral microvasculature [15, 17, 18]. 
Just like SP, CGRP plays an important role in the development of 
inflammatory pain and hyperalgesia in primary afferent neurons. 
Both CGRP (via the CGRP receptor) and SP (via the NK1 receptor) 
also act via different mechanisms to induce vasodilation [14, 15, 
19]. 
Cytokines
Interleukin-1 (IL-1) is produced by chondrocytes and other cells in 
the joints and plays an important role in cartilage degeneration by 
stimulating the synthesis of degenerative enzymes that inhibit the 
production of proteoglycans. Tumor necrosis factor α (TNF-α), 
and IL-6 appear to act synergistically with IL-1 and are all found 
in inflamed joints, along with SP and IL-1β [15]. IL-1 and IL-6 
are increased during stress or inflammation [15].
IL-6 is responsible for osteoporosis and induces hypersensitivity 
to pain and also fatigue and depression [15]. Release of TNF-α 
and IL-6 from monocytes/macrophages provokes neuropathic 
pain. IL-8 also promotes sympathetic pain [15]. The level of IL-1β 
is significantly correlated with the degree of pain (hyperalgesia), 
as well as TNF-α levels [15]. 
TNF-α may be a key player in the mediation of mechanical hyper-
algesia in neuropathic pain. Animal studies support a role for 
TNF-α in mechanical hyperalgesia. TNF-α can provoke ectopic 
nerve activity and neutralizing antibodies to the TNF receptor-1 
and reduce hyperalgesia in animals. In humans, elevated levels of 
soluble TNF receptor-1 (sTNF-R1) have been linked to allodynia 
in polyneuropathies. TNF-α can promote neurogenic inflam-
mation and neuropeptide release from nerve terminals and is 
more involved in sensitization processes within the nociceptive 
system than in directly provoking pain [20].
Interferon-gamma (IFN-γ) is a proinflammatory cytokine that 
is mainly released by T-lymphocytes and natural killer cells. It 
plays a pivotal role in the pathology of inflammatory diseases in 
the central nervous system, such as multiple sclerosis. It directly 
induces neuronal dysfunction and enhances glutamate neurotox-
icity mediated via the alpha-amino-3-hydroxy-5-methyl-4-isox-
azolepropionic (AMPA) receptor, not via the NMDA-receptor. 
One study provides findings for a novel mechanism of neuronal 
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excitotoxity, which may occur in both inflammatory and neurode-
generative diseases in the central nervous system [21]. 
Eicosanoids
Arachidonic acid is released by phospholipase A2 from phospho-
lipids. The prostanoids are metabolized into biologically active 
prostaglandins (PGs). Prostaglandin E2 (PGE2) is the principal 
proinflammatory prostanoid and contributes, in particular, to 
the two key features of inflammation, pain hypersensitivity and 
temperature changes. At the site of inflammation, PGE2 sensitizes 
peripheral nociceptors through activation of EP receptors present 
on sensory neurons, the phenomenon of peripheral sensitization. 
PGE2 is also produced in the spinal cord after tissue injury, where 
it contributes to central sensitization, an increase in the excit-
ability of spinal dorsal horn neurons that produces pain hyper-
sensitivity. PGE2, when produced at the site of tissue injury and 
inflammation, acts on capillaries to produce vasodilatation and 
edema and on macrophages to stimulate cytokine release [22].
By activation of the NK1 receptor, SP increases the production 
of PGE2 and evokes thermal hyperalgesia [14]. IL-1 also stimu-
lates the production of PGE2, contributing to vasodilation and 
pain. Following the release of TNF-α, there is an increase in 
the formation of PGE2, which can lead to edema formation by 
regulation of the vascular tone [15, 18]. 
Amino acids
A number of amino acids play an important role in the trans-
mission of pain. As described above, bradykinin increases sensi-
tization of pain via the NMDA receptors in the central nervous 
system by glutamate. Together with IFN-γ, glutamate contributes 
to neurotoxicity [21]. 
Levels of pain intensity are related to spinal fluid levels of arginine. 
Increased plasma arginine levels could result in vasoconstriction, 
diminished tissue blood distribution, and spread of pain [23]. 
Arginine is a precursor to nitric oxide (NO) and citrulline [15] 
and the citrulline/arginine ratio is regarded as an index of NO 
synthesis [24-26]. NO is also generated by macrophages and 
neutrophils as part of the human immune response [27].
The NO system has been hypothesized to be involved in depression. 
NO has been shown to modulate the effects of monoaminergic 
neurotransmitters such as serotonin, noradrenaline, and dopamine 
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and is thought to be involved in the pathogenesis of depression 
[24]. IFN-γ enhances the production of TNF-α and NO. Subse-
quent to the release of TNF-α, there is an increase in the formation 
of NO, which can lead to edema formation by regulation of the 
vascular tone [15, 18]. NO can modulate CGRP release and 
synthesis [28] and may also contribute to IL-1–induced degen-
eration of cartilage [15].
The enzyme glutaminase converts glutamine into glutamate. 
Furthermore, glutamine is used for the synthesis of urea in the 
liver, for renal ammoniagenesis, and for gluconeogenesis in both 
liver and kidney and as a major respiratory fuel for many cells 
[24, 29]. Glutamine inhibits the generation of arginine in cultured 
endothelial cells [30]. 
Glycine is a co-agonist of the NMDA receptor and is known to 
modulate immune cell responses in which the inhibitory effects 
on macrophages could be important [31]. It is mainly responsible 
for neuropathic pain, which manifests as allodynia and hyperal-
gesia [32]. 
The neurotransmitter serotonin (5-HT) is involved in many 
psychiatric disorders, including panic disorder, suicidal behavior, 
and depression. Plasma 5-HT has been suggested as a peripheral 
indicator of central serotonergic activity. Most of the 5-HT is 
stored in thrombocytes [33]. In blood vessels, 5-HT evokes 
vasoconstriction through activation of the 5-HT2A receptor. 
Important actions and functions of 5-HT are vascular constriction 
and contraction of other smooth muscles, increased microvas-
cular permeability, induction of blood platelet aggregation, stimu-
lation of peripheral nociceptive nerve endings, and excitation/
inhibition of neurons in the central nervous system. Clinical 
conditions associated with disturbed 5-HT function include 
migraine, carcinoid syndrome, mood disorders, and anxiety [34, 
35]. Moreover, platelet 5-HT release is inhibited by NO [36]. 
Taurine is found in high concentrations in muscle, brain, heart, 
and blood. This suggested that it is suggested that it may play 
an important role in neuromodulation, osmoregulation, and 
thermoregulation. Antihypertensive effects of taurine have been 
demonstrated in several experimental models. Several rat models 
suggest that taurine plays an important role in the maintenance 
and regulation of vascular tone in normal and pathological condi-
tions [37]. It has been reported that taurine reduces cyclic GMP, 
which evokes vasodilation [38]. The release of taurine in various 
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cell-damaging conditions, including ischemia and increased free 
radical production, has been shown [39]. Taurine in turn has 
antioxidative properties [40]. Very recently, it has been shown that 
taurine can diminish neuropathic nociception, possibly through 
interaction with the glycine receptor [41]. 
Hypothesis and Aim 
Our hypothesis is that a variety of mediators of inflammation are 
present in tissue fluid of CRPS1 patients in the initial stage of the 
disease, causing the clinical signs and symptoms seen in CRPS1, 
which resemble the characteristics of inflammation. Furthermore, 
it was hypothesized that the inflammatory process would diminish 
over time by normalization of these mediators of inflammation. 
The aim of this thesis was to measure these potential mediators in 
the plasma and fluid of artificially induced skin blisters of CRPS1 
patients. Furthermore, we sought to determine whether these 
mediators are responsible for the characteristics of CRPS1 and to 
characterize the relationship between cytokine levels in plasma 
and blister fluid and duration of the disease. The following disease 
characteristics were assessed: pain, differences in temperature, 
volume, and mobility between the extremities, and psychological 
dysfunction. 
16
16
References
1. Janig, W. and R. Baron,Complex regional pain syndrome: mystery explained? Lancet Neurol, 
2003. 2(11): p. 687-97.
2. Bruehl, S., R.N. Harden, B.S. Galer, S. Saltz, M. Backonja, and M. Stanton-Hicks, Complex 
regional pain syndrome: are there distinct subtypes and sequential stages of the syndrome? 
Pain, 2002. 95(1-2): p. 119-24.
3. Veldman, P.H., H.M. Reynen, I.E. Arntz, and R.J. Goris, Signs and symptoms of reflex sympa-
thetic dystrophy: prospective study of 829 patients.Lancet, 1993. 342(8878): p. 1012-6.
4. Stanton-Hicks, M., W. Janig, S. Hassenbusch, J.D. Haddox, R. Boas, and P. Wilson, Reflex 
sympathetic dystrophy: changing concepts and taxonomy. Pain, 1995. 63(1): p. 127-33.
5. Harden, R.N., S. Bruehl, B.S. Galer, S. Saltz, M. Bertram, M. Backonja, R. Gayles, N. 
Rudin, M.K. Bhugra, and M. Stanton-Hicks, Complex regional pain syndrome: are the IASP 
diagnostic criteria valid and sufficiently comprehensive? Pain, 1999. 83(2): p. 211-9.
6. Bruehl, S., R.N. Harden, B.S. Galer, S. Saltz, M. Bertram, M. Backonja, R. Gayles, N. Rudin, 
M.K. Bhugra, and M. Stanton-Hicks, External validation of IASP diagnostic criteria for 
Complex Regional Pain Syndrome and proposed research diagnostic criteria. International 
Association for the Study of Pain. Pain, 1999. 81(1-2): p. 147-54.
7. de Mos, M., A.G. de Bruijn, F.J. Huygen, J.P. Dieleman, B.H. Stricker, and M.C. Sturkenboom, 
The incidence of complex regional pain syndrome: a population-based study.Pain, 2007. 
129(1-2): p. 12-20.
8. Bonica, J.J., Evolution and current status of pain programs. J Pain Symptom Manage, 1990. 
5(6): p. 368-74.
9. Schwartzman, R.J. and J. Kerrigan, The movement disorder of reflex sympathetic dystrophy. 
Neurology, 1990. 40(1): p. 57-61.
10. Schwartzman, R.J. and T.L. McLellan, Reflex sympathetic dystrophy. A review. Arch Neurol, 
1987. 44(5): p. 555-61.
11. Munnikes, R.J., C. Muis, M. Boersma, C. Heijmans-Antonissen, F.J. Zijlstra, and F.J. Huygen, 
Intermediate stage complex regional pain syndrome type 1 is unrelated to proinflammatory 
cytokines. Mediators Inflamm, 2005(6): p. 366-72.
12. Huygen, F.J., S. Niehof, J. Klein, and F.J. Zijlstra, Computer-assisted skin videothermography 
is a highly sensitive quality tool in the diagnosis and monitoring of complex regional pain 
syndrome type I. Eur J Appl Physiol, 2004. 91(5-6): p. 516-24.
13. Wang, H., T. Kohno, F. Amaya, G.J. Brenner, N. Ito, A. Allchorne, R.R. Ji, and C.J. Woolf, 
Bradykinin produces pain hypersensitivity by potentiating spinal cord glutamatergic synaptic 
transmission. J Neurosci, 2005. 25(35): p. 7986-92.
14. Tang, H.B., Y.S. Li, K. Arihiro, and Y. Nakata, Activation of the neurokinin-1 receptor by 
substance P triggers the release of substance P from cultured adult rat dorsal root ganglion 
neurons.Mol Pain, 2007. 3(1): p. 42.
15. Omoigui, S., The biochemical origin of pain: the origin of all pain is inflammation and the 
inflammatory response. Part 2 of 3 - inflammatory profile of pain syndromes. Med Hypotheses, 
2007. 69(6): p. 1169-78.
17
1
17
16. Gradl, G., B. Finke, S. Schattner, P. Gierer, T. Mittlmeier, and B. Vollmar, Continuous intra-
arterial application of substance P induces signs and symptoms of experimental complex 
regional pain syndrome (CRPS) such as edema, inflammation and mechanical pain but no 
thermal pain. Neuroscience, 2007. 148(3): p. 757-65.
17. Leis, S., M. Weber, M. Schmelz, and F. Birklein, Facilitated neurogenic inflammation in 
unaffected limbs of patients with complex regional pain syndrome. Neurosci Lett, 2004. 
359(3): p. 163-6.
18. Starr, A., R. Graepel, J. Keeble, S. Schmidhuber, N. Clark, A. Grant, A.M. Shah, and S.D. Brain, 
A reactive oxygen species-mediated component in neurogenic vasodilatation. Cardiovasc Res, 
2008.
19. Greco, R., C. Tassorelli, G. Sandrini, P. Di Bella, S. Buscone, and G. Nappi, Role of calcitonin 
gene-related peptide and substance P in different models of pain. Cephalalgia, 2008. 28(2): p. 
114-26.
20. Maihofner, C., H.O. Handwerker, B. Neundorfer, and F. Birklein, Mechanical hyperalgesia in 
complex regional pain syndrome: a role for TNF-alpha? Neurology, 2005. 65(2): p. 311-3.
21. Mizuno, T., G. Zhang, H. Takeuchi, J. Kawanokuchi, J. Wang, Y. Sonobe, S. Jin, N. Takada, 
Y. Komatsu, and A. Suzumura, Interferon-{gamma} directly induces neurotoxicity through 
a neuron specific, calcium-permeable complex of IFN-{gamma} receptor and AMPA GluR1 
receptor. Faseb J, 2008.
22. Lin, C.R., F. Amaya, L. Barrett, H. Wang, J. Takada, T.A. Samad, and C.J. Woolf, Prosta-
glandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity. J Pharmacol Exp 
Ther, 2006. 319(3): p. 1096-103.
23. Groeneweg, J.G., F.J. Huygen, C. Heijmans-Antonissen, S. Niehof, and F.J. Zijlstra, Increased 
endothelin-1 and diminished nitric oxide levels in blister fluids of patients with intermediate 
cold type complex regional pain syndrome type 1. BMC Musculoskelet Disord, 2006. 7: p. 
91.
24. Fekkes, D., M. Bannink, W.H. Kruit, A.R. Van Gool, P.G. Mulder, S. Sleijfer, A.M. Eggermont, 
and G. Stoter, Influence of pegylated interferon-alpha therapy on plasma levels of citrulline 
and arginine in melanoma patients. Amino Acids, 2007. 32(1): p. 121-6.
25. Dewanjee, M.K., Molecular biology of nitric oxide synthases. Reduction of complications 
of cardiopulmonary bypass from platelets and neutrophils by nitric oxide generation from 
L-arginine and nitric oxide donors. Asaio J, 1997. 43(3): p. 151-9.
26. Jugdutt, B.I., Nitric oxide and cardioprotection during ischemia-reperfusion. Heart Fail Rev, 
2002. 7(4): p. 391-405.
27. Janaway, C., P. Travers, M. Walport, and M. Shlomchik, 2005. Immunobiology: the immune 
system in health and disease. 0-8153-4101-6.
28. Ghatta, S. and N. D, Calcitonin gene-related peptide: Understanding its role. Indian J 
Pharmacol 2004. 36: p. 277-283.
29. Curthoys, N.P. and M. Watford, Regulation of glutaminase activity and glutamine metabolism. 
Annu Rev Nutr, 1995. 15: p. 133-59.
30. Sessa, W.C., M. Hecker, J.A. Mitchell, and J.R. Vane, The metabolism of L-arginine and its 
18
18
significance for the biosynthesis of endothelium-derived relaxing factor: L-glutamine inhibits 
the generation of L-arginine by cultured endothelial cells. Proc Natl Acad Sci U S A, 1990. 
87(21): p. 8607-11.
31. Schilling, T. and C. Eder, A novel physiological mechanism of glycine-induced immuno-
modulation: Na+-coupled amino acid transporter currents in cultured brain macrophages. J 
Physiol, 2004. 559(Pt 1): p. 35-40.
32. Jorum, E., T. Warncke, and A. Stubhaug, Cold allodynia and hyperalgesia in neuropathic 
pain: the effect of N-methyl-D-aspartate (NMDA) receptor antagonist ketamine--a double-
blind, cross-over comparison with alfentanil and placebo. Pain, 2003. 101(3): p. 229-35.
33. Fekkes, D., L. Timmerman, and L. Pepplinkhuizen, Effects of clomipramine on plasma amino 
acids and serotonergic parameters in panic disorder and depression. Eur Neuropsychophar-
macol, 1997. 7(3): p. 235-9.
34. Houston, D.S. and P.M. Vanhoutte, Serotonin and the vascular system. Role in health and 
disease, and implications for therapy. Drugs, 1986. 31(2): p. 149-63.
35. Roberts, M.H., Involvement of serotonin in nociceptive pathways.  Drug Des Deliv, 1989. 
4(2): p. 77-83.
36. Juhasz, G., T. Zsombok, E.A. Modos, S. Olajos, B. Jakab, J. Nemeth, J. Szolcsanyi, J. Vitrai, 
and G. Bagdy, NO-induced migraine attack: strong increase in plasma calcitonin gene-related 
peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain, 
2003. 106(3): p. 461-70.
37. Niu, L.G., M.S. Zhang, Y. Liu, W.X. Xue, D.B. Liu, J. Zhang, and Y.Q. Liang, Vasorelaxant 
effect of taurine is diminished by tetraethylammonium in rat isolated arteries. Eur J Pharmacol, 
2008. 580(1-2): p. 169-74.
38. Hilgier, W., E. Anderzhanova, S.S. Oja, P. Saransaari, and J. Albrecht, Taurine reduces 
ammonia- and N-methyl-D-aspartate-induced accumulation of cyclic GMP and hydroxyl 
radicals in microdialysates of the rat striatum. Eur J Pharmacol, 2003. 468(1): p. 21-5.
39. Saransaari, P. and S.S. Oja, Characteristics of taurine release induced by free radicals in 
mouse hippocampal slices. Amino Acids, 2004. 26(1): p. 91-8.
40. Zhang, M., I. Izumi, S. Kagamimori, S. Sokejima, T. Yamagami, Z. Liu, and B. Qi, Role of 
taurine supplementation to prevent exercise-induced oxidative stress in healthy young men. 
Amino Acids, 2004. 26(2): p. 203-7.
41. Pellicer, F., A. Lopez-Avila, U. Coffeen, J. Manuel Ortega-Legaspi, and R.D. Angel, Taurine 
in the anterior cingulate cortex diminishes neuropathic nociception: a possible interaction 
with the glycine(A) receptor.
  Eur J Pain, 2007. 11(4): p. 444-51. 
19
Chapter 2
Tumor necrosis factor-α and interleukin-6 are not correlated 
with the characteristics of CRPS type 1 in 66 patients
Feikje Wesseldijk
Frank J.P.M. Huygen
Claudia Heijmans-Antonissen
Sjoerd P. Niehof
Freek J. Zijlstra
Published in European Journal of Pain Volume12, p 716-721, 
August 2008
20
21
2
21
Abstract  
It was previously shown in a group of 9 patients with Complex 
Regional Pain Syndrome type 1 (CRPS1) that levels of the proin-
flammatory cytokines tumor necrosis factor-α (TNF-α) and inter-
leukin-6 (IL-6) are higher in blister fluid from the involved side. 
We hypothesize that local inflammation is responsible for the 
characteristics of CRPS1. The aim of this study was to confirm 
the previous observation in a large group of CRPS1 patients, 
repeating the measurement of TNF-α and IL-6 in blister fluid. 
Furthermore, we sought to determine whether these cytokines are 
responsible for the characteristics of CRPS1 and characterize the 
relationship between cytokine levels and duration of the disease. 
Sixty-six patients with CRPS1 participated. Skin blisters were 
artificially induced for measurement of cytokines in both extrem-
ities. The following disease characteristics were assessed: pain 
and differences in temperature, volume, and mobility between the 
extremities. TNF-α and IL-6 levels were significantly higher in 
blister fluid from the involved side. However, cytokine levels did 
not correlate with the characteristics or duration of the disease. 
Our findings confirm the presence of local inflammation in a 
population of 66 patients in the first 2 years of CRPS1. Proinflam-
matory cytokines seem to be only partly involved in the pathophys-
iology of CRPS1, as indicated by the lack of coherence between 
TNF-α and IL-6 levels and the signs and symptoms of inflam-
mation and disease duration. Other inflammatory mediators and 
mechanisms, such as central sensitization, are probably involved 
in the early stages of CRPS1.  
Introduction 
Complex Regional Pain Syndrome type 1 (CRPS1) is a disease 
of the extremity that usually occurs as a complication after sur-
gery or trauma, although spontaneous occurrence has also been 
described [1]. 
In a recent epidemiological study in the Netherlands, the incidence 
of CRPS1 for fractures was estimated to be approximately 26.2 
per 100,000 person years, with a median age of onset of 52.7 
years. CRPS1 occurs more often in females than in males, the 
ratio being approximately 3.4:1. Whereas the upper extremity is 
more often affected than the lower extremity, the right and the left 
sides of the body are affected with the same frequency [2].
The pathophysiology of CRPS1 remains a matter of debate. In 
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general, three mechanisms are thought to be involved: afferent 
mechanisms (e.g. neurogenic inflammation) [3-5], efferent 
mechanisms (e.g. autonomic disturbances) [6], and central 
nervous system mechanisms (e.g. cerebral plasticity) [7]. Based 
on our review of the literature regarding CRPS pathophysi-
ology, we hypothesize that after trauma or surgery, the normal 
sterile inflammatory response is exacerbated by a genetic and/
or acquired immunologic disorder [8]. Neuroimmune activation 
of cells in the peripheral nervous system, which is part of the 
afferent mechanism, apparently results in central sensitization 
and exacerbation of pain [9]. Neuropeptides, cytokines, and other 
mediators are released during the inflammation [10, 11] and 
cause the prominent signs and symptoms, which resemble inflam-
mation; these include increased skin temperature, edema, pain, 
loss of function, and redness [8, 12].
In our previous work involving 9 CRPS1 patients, we found 
higher levels of the initially produced proinflammatory cytokines 
tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in artifi-
cially induced skin blisters on the involved side. These observa-
tions suggest local inflammation [10, 13]. The aim of this study 
was to confirm the previous observation by measuring TNF-α and 
IL-6 in blister fluid in a larger group of CRPS1 patients, all of 
whom fulfill the diagnostic criteria described by Bruehl et al. [14]. 
Furthermore, we sought to determine whether these cytokines 
cause the characteristic signs and symptoms of the syndrome and 
to investigate the correlation between cytokine levels and disease 
duration.
Methods
Patients
Sixty-six patients with CRPS1 in one extremity, as defined by the 
diagnostic criteria of Bruehl, participated [14]. Patients with other 
diseases that could explain the signs and symptoms were excluded. 
The patients participated in several studies conducted between 
2001 and 2005 to investigate the pathophysiology of CRPS1 or 
the effects of specific treatments for CRPS1 [10, 13, 15, 16]. The 
protocol was approved by the Medical Ethics Committee of the 
Erasmus MC Rotterdam (MEC no. 1989.780/2001/24). Guide-
lines according to the Declaration of Helsinki (amended version 
of 2002) and Good Clinical Practice (ICH/GCP version 1996) 
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were followed. Data collection and calculations were performed 
according to guidelines for registration of personal data.
Data collected before the start of these treatments (T0) were used 
to describe the patients, so none of the treatments would affect the 
results of the measurements in the current study.
Pain assessment
Patients rated their pain intensity using a Visual Analogue Scale 
(VAS) ranging from 0-100 mm [17]. 
Temperature measurement 
Skin temperature was measured using an infrared tympanic probe 
thermometer (First Temp Genius®; Sherwood Medical Crawley, 
Sussex, UK) [18]. Measurements were obtained on the dorsal 
aspect of the hand or foot in a matrix of five points. The difference 
in mean temperature between the involved and contralateral 
extremities was calculated. 
Assessment of volume
Volume was measured with a volumeter, which measures the 
amount of water displaced by immersion of a body part [19]. The 
difference between the involved and contralateral extremities was 
calculated as a percentage of the contralateral extremity. 
Assessment of mobility
Mobility was assessed by measuring the active range of motion 
(AROM), which is defined as the arc of motion requiring muscle 
power to achieve the motion of a joint. In the upper extremity, 
the AROM was measured for dorsal and palmar flexion in of the 
wrist, and for flexion and extension of the metacarpophalangeal 
and proximal interphalangeal joints of digits 1, 2, and 3 [20]. In 
the lower extremity, the AROM was measured for flexion and 
extension of the knee, ankle, and digit 1 of the foot, and inversion 
and eversion of the ankle [21]. 
The position of the patients and the method of measurement 
were standardized for each joint, in accordance with the clinical 
assessment recommendations of the American Society of Hand 
Therapists [22]. The AROM on the involved extremity was 
multiplied by 100 and divided by the AROM on the contralateral 
extremity to derive the percentage of normal mobility. 
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Blisters
Blisters were induced using a suction method [10, 15, 23]. A skin 
suction chamber was positioned on the skin of the involved and 
contralateral extremities. A vacuum of 300 mmHg was applied 
with an Atmoforte 350A aspirator pump (ATMOS Medizin-
technik, Lenzkirch, Germany). After 15 min, the vacuum was 
reduced to 250 mmHg, and after another 15 min it was reduced 
to 200 mmHg. This negative pressure was maintained for 2-2.5 
hours. The blisters created were punctured, and fluid was pooled 
from each side into a 1.5-ml Eppendorf conical polypropylene 
tube and centrifuged for 5 min at 1600 xg. The mean recovery of 
supernatants was 152 ± 103 (SD) µl for the involved side and 153 
± 99 µl for the contralateral side. All samples were stored in 1-ml 
conical polypropylene tubes at -80 °C until analysis [10, 23]. 
Cytokine assays
Blister fluid samples were diluted (mean dilution factor 4.1 ± 
1.6) in appropriate calibrator diluent assay buffer for the direct 
measurement of cytokines. Cytokine assays were performed 
following the manufacturer’s protocol (PeliKine™ human ELISA 
kits for IL-6 [M1906] and TNF-α [M1920]; CLB, Amsterdam, 
the Netherlands). The standard curve ranges and mean calculated 
zero signal ± 3 (SD) were 0-80 and 0.3 pg/ml for IL-6 and 0-1000 
and 1 pg/ml for TNF-α. The absorbance per well was measured at 
450 nm with a Medgenix EASIA reader. Sample concentrations 
were calculated using the appropriate standard calibration lines 
and the Softmax® software of the reader. 
Statistical analysis
Data were analyzed using SPSS for Windows, version 14.0. The 
nonlinear distributed data of cytokine content in blister fluid and 
the objective parameters temperature, volume, and AROM were 
described as median and ranges. The linear distributed data of 
the subjective parameter pain was described as the median and 
SD. Paired samples were compared using the Wilcoxon signed 
ranks test, and correlations were analyzed using Spearman’s rank 
correlation test.
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Table 1. Characteristics of the study population
Patient characteristic Value
Data are presented as the n or median (range)
Results
Patient characteristics are presented in Table 1. All 66 patients 
reported continuing pain that was disproportionate to the inciting 
event. For the sensory category of the Bruehl criteria set, 100% 
reported an abnormality in sensation of the extremity. Similarly, 
for the vasomotor category, sudomotor/edema category, and 
motor/trophic category, 100% of the population reported an 
abnormality for the involved side. At physical examination, 76% 
of the patients had a difference in sensation of the skin, 98% 
had a difference in vasomotor signs between sides, 94% had a 
difference in the sudomotor/edema category between sides, and 
94% had an abnormality in the motor/trophic category. Table 2 
lists all signs and symptoms for the four categories separately.
The signs and symptoms of impairment were assessed in terms 
of the subjective parameter pain and the objective parameters 
temperature, volume, and mobility. Patients reported a VAS 
score with a median of 55 mm (SD 22). In the first 2 years of the 
disease, 41% of the population had a warm extremity (median 
difference between involved and contralateral side 0.5 ºC, range 
0.02 to 4.1), whereas 56% had a cold extremity (median -1.0 ºC, 
range -4.8 to -0.02). Three percent of patients did not show any 
difference in temperature. Approximately the same distribution 
was found for edema (39% of the patients; median difference 
5.9% of the contralateral side, range 0.8 to 10.4) and atrophy (59% 
of the patients; median difference -0.8% of the contralateral side, 
range -0.3 to -1.1). In 95% of the patients, mobility was lower 
for the involved versus contralateral side (median 69.7% of the 
contralateral side, range 0.3% to 97.7%), whereas in 5% of the 
patients, mobility of the involved extremity was better (median 
103.8% of the contralateral side, range 101.3 to 121.7).
Gender: male/female
Age in years
Duration of CRPS1, months
Location: upper/lower extremity
Side: right/left 
Cause: trauma (fracture, accident)/surgery/
spontaneous/other
16/50
48 (21-78)
7 (1-168)
50/16
34/32 
40 (25, 15)/17/2/7
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In 57 of the 66 patients, skin blisters were successfully induced. 
Levels of TNF-α and IL-6 were significantly higher in the blister 
fluid from the involved versus contralateral extremity (Table 3). 
For 74% of the patients, the levels of TNF-α were elevated on 
the involved side (median difference between the involved and 
contralateral side 23 pg/ml, range 1 to 718 pg/ml). For 25% of 
the patients, the levels of TNF-α were lower on the involved 
side (median difference between the involved and contralateral 
side -18 pg/ml, range -295 to -1 pg/ml). For 1% of patients, no 
difference was found. For 84% of the patients, the levels of IL-6 
were elevated on the involved side (median difference between 
the involved and contralateral side 44 pg/ml, range 1 to 626 pg/
ml). In 12% of the patients, the levels of IL-6 were lower on 
the involved side (median difference between the involved and 
contralateral side -8 pg/ml, range -258 to -2 pg/ml). In 4%, no 
difference was found between the two sides. 
There was a significant correlation between the differences in 
TNF-α and IL-6 between sides (Spearman’s correlation coeffi-
cient = 0.79; p < 0.001). There was no significant correlation 
between the cytokines and typical characteristics of inflammation 
such as pain, heat, edema, and loss of function or duration of the 
disease. 
Table 3. Data on TNF-α and IL-6 levels in blister fluid in the involved and 
contralateral extremities. 
Data are presented as median (range)
* Wilcoxon signed-ranks test P < 0.001
Discussion 
In 66 CRPS1 patients in the first two years of the disease, levels 
of the proinflammatory cytokines TNF-α and IL-6 were signifi-
cantly higher in the involved versus contralateral extremity. These 
findings are in agreement with earlier results found in a group of 
nine CRPS1 [10, 15].
In an earlier study, we found high levels of the proinflammatory 
cytokines IL-6 and TNF-α in suction blisters on the affected 
extremity, supporting the theory that CRPS1 is associated 
Involved side
28 (1–795)*
43 (1– 662)*
Contralateral side
14 (1– 616)
3 (1– 434)
TNF-α (pg/ml)
IL-6 (pg/ml)
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with pathogenic local inflammation [10, 16]. This finding was 
confirmed in the current study. The involvement of TNF-α was 
further suggested by the success of anti-TNF treatment of CRPS1 
[13] and the significant elevation of soluble TNF-α receptor 
type I (sTNF-RI) in CRPS1, particularly in combination with 
mechanical hyperalgesia [24]. Maihofner et al. (2005) reported 
that levels of this protein significantly correlate with TNF-α 
in CRPS1. Furthermore, elevated levels of IL-8 and sTNF-RI/
II indicate an association between CRPS1 and an inflammatory 
process. Normal plasma levels of white blood cells, C-reactive 
protein, and IL-6 suggest a local process [25]. Another finding 
supporting the theory of an excessive inflammatory reaction is the 
increased extravasation of indium-labelled immunoglobulin as a 
sign of increased capillary permeability to macromolecules [26]. 
A recent finding suggests that there is an ongoing inflammatory 
response in the form of increased leukocyte accumulation on the 
involved side [27]. 
In contrast, several studies found no indication of an inflammatory 
process. No association was found between immune activation 
and CRPS1 [28], and no difference was found between patients 
and controls in the production of proinflammatory and anti-
inflammatory cytokines in plasma [29]. The lack of high levels 
of inflammatory cytokines in the circulation supports the idea 
of local inflammation, as suggested by previous findings using 
the skin blister method [10, 23]. Patient selection might also 
contribute to the difference in findings. Both of the above studies 
included patients with longstanding CRPS1; it is possible that the 
immune response diminishes over the course of the disease. 
Because levels of TNF-α and IL-6 were higher on the involved 
side in our group, one might expect that these markers of inflam-
mation would be related to the characteristic signs and symptoms 
of inflammation. However, there was no correlation. An expla-
nation for the absence of the correlation is that the changes in 
temperature, volume, AROM and pain in CRPS1 are irregularly 
distributed across the hand or foot. 
In an ongoing inflammatory process, one would also expect a local 
increase in skin temperature and blood flow [1]. However, 41% 
of the patients in our study had a higher skin temperature for the 
involved extremity and 56% had a lower skin temperature for the 
involved extremity. There was no significant difference between 
these two groups in the levels of the proinflammatory cytokines. 
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Several studies confirm this observation, even describing a 
primarily cold CRPS1 [5, 11, 30, 31]. A possible explanation for 
this could be that blood flow, and thus skin temperature, is the 
result of not only afferent but also efferent mechanisms. Distur-
bances in central temperature regulation could result in altered 
(local) temperature of the injured extremity [32-34]. 
The profound changes in macrovascular and microvascular 
perfusion in patients with systemic inflammatory response 
syndrome (SIRS) and sepsis also contribute to edema in the 
CRPS1-affected arm and support an inflammatory-associated 
pathogenesis for some CRPS1 symptoms [25]. In this study 
swelling was reported by 96% of the patients, and in 87% swelling 
of the involved side was observed by a physician. Contrary to 
these findings, we measured edema on the involved side in only 
39% of patients. No significant difference was found in the levels 
of TNF-α and IL-6 between the group with and without edema 
measured with the volumeter. It is possible that edema is also 
affected by other inflammatory mediators such as calcitonin 
gene-related peptide (CGRP) and substance P (SP), and related 
mechanisms. Alternatively, volumeter-based measurement of the 
differences between the involved and contralateral extremities 
might not be sufficiently accurate. 
Earlier work revealed a slight decline in TNF-α and IL-6 between 
the acute stage (median 6 months, interquartile range 2-12 months) 
and the intermediate stage (median 30 months, interquartile 
range 23-40 months) of CRPS1, but showed that the levels are 
still significantly higher on the affected side. However, impair-
ments of volume, mobility, and pain on the involved side, are 
significantly reduced compared to the acute stage. This suggests 
that the initiation and sustained development of CRPS1 are at 
least partially affected by proinflammatory cytokines. However, 
the mechanism is more complex, involving a number of cells, 
such as monocytes, tissue macrophages, and mast cells [16]. 
Another possible pathophysiologic mechanism for CRPS1 might 
be neurogenic inflammation, as suggested by the increased levels 
of systemic CGRP in patients with acute CRPS1 contributing 
to vasodilation, edema, and increased sweating. Improvement 
of the clinical signs and symptoms is followed by a significant 
reduction in CGRP levels [35]. Moreover, the increased release of 
neuropeptides in CRPS1 in response to transcutaneous electrical 
stimulation suggests facilitated neurogenic inflammation [36]. 
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Other indications of neurogenic inflammation are the increased 
SP-induced plasma protein extravasation in CRPS1 patients in 
the affected and unaffected limbs [37] and the significant increase 
in IL-1β and IL-6, but not TNF-α, in the cerebrospinal fluid of 
CRPS1 patients versus controls [9].
In the first two years, a number of our patients exhibited reduced 
temperature and signs of atrophy. Disease duration did not 
correlate with cytokine levels. However, all patients fulfilled the 
criteria of Bruehl [14], suggesting that various subpopulations, as 
described by others, were included [30, 38, 39]. It would be inter-
esting to investigate differences in immune parameters among 
these various subpopulations in future studies.
In conclusion, this study confirms the presence of local inflam-
mation in CRPS1 in a large population of 66 patients in the first 2 
years of the disease. Proinflammatory cytokines seem to be only 
partly involved in the pathophysiology, as indicated by the lack 
of coherence between levels of TNF-α and IL-6 and the signs 
and symptoms of inflammation and disease duration, as measured 
with the regularly used assessment instruments for CRPS1. Other 
inflammatory mediators and other mechanisms such as central 
sensitization are probably involved in the early stages of the 
disease.  
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Abstract 
In an earlier study, levels of the proinflammatory cytokines TNF-α 
and IL-6 are higher in blisters fluid from the CRPS1 (complex 
regional pain syndrome type 1) side obtained at 6 and 30 months 
(median) after the initial event. The aim of this follow-up study 
is to determine the involvement of these cytokines in long lasting 
CRPS1. Twelve CRPS1 patients, with median disease duration 
of 72 months, participated. The levels of TNF-α and IL-6 were 
measured in blister fluid; disease activity was reevaluated by 
measuring pain and differences in temperature, volume, and 
mobility between both extremities. Differences in levels of IL-6 
and TNF-α and mobility between both sides were significantly 
decreased. Pain and differences in temperature and volume were 
not significantly altered. No correlation was found between the 
cytokines and the disease characteristics. These results indicate 
that IL-6 and TNF-α are only partially responsible for the signs 
and symptoms of CRPS1. 
Introduction 
Complex regional pain syndrome type 1 (CRPS1) is a disease of 
an extremity that usually occurs as a complication after surgery or 
trauma, although spontaneous occurrence is also described [1]. 
The pathophysiology of CRPS1 is still not totally clear. In general, 
three mechanisms are thought to be involved: afferent mecha-
nisms (e.g. neurogenic inflammation) [2-4], efferent mechanisms 
(e.g. autonomic disturbances) [5], and central nervous system 
mechanisms (e.g. cerebral plasticity) [6]. Based on our review of 
the literature regarding the CRPS pathophysiology, we hypothe-
sized that following a trauma or surgery, the normal sterile inflam-
matory response runs out of control, and is perhaps initiated by a 
genetic and/or acquired immunologic disorder [7]. Neuroimmune 
activation of cells in the peripheral nervous system, which is part 
of the afferent mechanism, apparently results in central sensiti-
zation and exacerbation of pain [8]. Neuropeptides, cytokines, 
and other mediators are released during the inflammation [9, 10] 
and cause the prominent signs and symptoms, which resemble 
inflammation; these include increased skin temperature, edema, 
pain, loss of function, and redness [7, 11]. 
Levels of TNF-α and IL-6 were previously shown to be elevated 
in fluid of artificially induced skin blisters from the CRPS1 side 
in the initial stage of the disease [9, 12, 13]. These observations 
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suggest local inflammation. We hypothesized that in most patients 
local inflammation would only be present during the first year 
of the disease, since the clinical signs and symptoms of CRPS1 
are expected to diminish over time in most patients. Therefore, 
we predicted that the formation of proinflammatory mediators 
(such as IL-6 and TNF-α) should decline during the course of the 
disease. In an earlier study, we showed that although the levels of 
TNF-α and IL-6 declined in the intermediate stage of the disease, 
they were still significantly elevated in the CRPS1 extremity 
[13].  In the present study, we examine whether this decline in 
cytokine levels continues during the course of the disease and 
whether this decline is correlated with a possible improvement 
in disease activity as measured by registration of pain, and by the 
measurement of differences in temperature, volume, and mobility 
between the CRPS1 and contralateral extremities.
Materials and methods
The protocol was approved by the Medical Ethics Committee of 
the Erasmus MC Rotterdam (MEC no. 1989.780/2001/24). Guide-
lines according to the Declaration of Helsinki (amended version 
of 2002) and Good Clinical Practice (ICH/GCP version 1996) 
were followed. Data collection and calculations were performed 
according to guidelines for registration of personal data.
Patients
Sixty-six patients with CRPS1 in one extremity for 7 months 
after the initial event participated in several studies conducted 
between April 2001 and February 2004 (T0) to investigate the 
pathophysiology of CRPS1 or the effects of specific treatments 
for CRPS1 [9, 12, 14]. At the time of the first follow-up study in 
2004, 25 patients with CRPS1 with a median disease duration of 
30 months after the initial event agreed to participate (T1) [13]. 
In 2007 these 25 patients were again asked to participate. One 
patient had died, one patient appeared to have CRPS type 2, and 
11 patients chose not to participate again. In the end, 12 patients 
with CRPS1 were included in this study (T2).
For this study, we used the results obtained at baseline (T0), first 
follow-up measurement (T1) and second follow-up measurement 
(T2) from only these 12 patients. All 12 patients fulfilled the 
CRPS1 criteria by Bruehl et al. [15] at the first measurement (T0), 
performed shortly after the initial event (median 4 months) which 
resulted in the development of the disease. 
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Pain assessment
The intensity of pain was assessed by using a visual analogue 
scale (VAS) recorded in 0–100 millimeters [16]. The McGill 
Pain Questionnaire, Dutch Language Version (MPQ-DLV), was 
measured by counting the total number of words chosen from 20 
items [17].
Temperature measurement 
Skin temperature was measured using an infrared tympanic probe 
thermometer (First Temp Genius®; Sherwood Medical Crawley, 
Sussex, UK) [18]. Measurements were obtained on the dorsal 
aspect of the hand in a matrix of five points. The difference in 
mean temperature between the CRPS1 and contralateral extrem-
ities was calculated, and the data were expressed with respect to 
the temperature of the unaffected hand. 
Assessment of volume
Volume was measured with a volumeter, which measures the 
amount of water displaced by immersion of a body part [19]. The 
difference between the CRPS1 and contralateral extremities was 
calculated as a percentage of the contralateral extremity. 
Assessment of mobility
Mobility was assessed by measuring the active range of motion 
(AROM), which is defined as the arc of motion requiring muscle 
power to achieve the motion of a joint [20, 21]. The AROM on 
the CRPS1 extremity was multiplied by 100 and divided by the 
AROM on the contralateral extremity to derive the percentage of 
normal mobility. 
Blisters
Artificial skin blisters were induced using a suction method [9, 
14, 22]. A skin suction chamber was positioned on the skin of the 
CRPS1 and contralateral extremities. A vacuum of 300 mm Hg 
was applied with an Atmoforte 350A aspirator pump (ATMOS 
Medizintechnik, Lenzkirch, Germany). After 15 min, the vacuum 
was reduced to 250 mm Hg, and after another 15 min it was 
reduced to 200 mm Hg. This negative pressure was maintained 
for 2-2.5 h. The blisters created were punctured, and fluid was 
pooled from each side into a 1.5-ml Eppendorf conical polypro-
pylene tube and centrifuged for 5 min at 1600 x g. All samples 
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were stored in 1-ml conical polypropylene tubes at -80 °C until 
analysis [9, 22]. 
Cytokine assays
Blister fluid samples were diluted 4-fold in appropriate calibrator 
diluent assay buffer for the direct measurement of cytokines. 
Cytokine assays were performed following the manufacturer’s 
protocol (PeliKine™ human ELISA kits for IL-6 [M1906] and 
TNF-α [M1920]; CLB, Amsterdam, the Netherlands). The 
standard curve ranges and mean calculated zero signal ± 3 (SD) 
were 0-80 and 0.3 pg/ml for IL-6 and 0-1000 and 1 pg/ml for 
TNF-α. The absorbance per well was measured at 450 nm with a 
Medgenix EASIA reader. Sample concentrations were calculated 
using the appropriate standard calibration lines and the Softmax® 
software of the reader. 
Statistical analysis
Data were analyzed with SPSS ® for Windows, version 14.0. 
To determine whether the 12 CRPS1 patients from this study 
were a representative group of the initial 66 CRPS1 patients 
who started the follow-up study, the one-way ANOVA test was 
used for a comparison between groups for the pro-inflammatory 
cytokines, and the outcome parameters pain, temperature, volume 
and mobility. To determine if the differences in means for these 
selected parameters were significantly different from 0, we 
applied the one-sample t-test for comparisons of the levels of the 
pro-inflammatory cytokines between both extremities, and to the 
differences in the outcome parameters of temperature, volume, 
and mobility. Mixed model analysis was used to compare the 
differences between both extremities to each other for the levels 
of the cytokines, VAS, McGill, temperature, volume and mobility 
between each time point. Correlations between the differences 
in levels of IL-6 and TNF-α and the outcome parameters were 
calculated using the Pearson Correlation test. Significance was 
accepted at the p < 0.05 (two-sided) level.
Results
The group of 12 CRPS1 patients was a good representation of the 
original group of 66 CRPS1 patients with which we initiated the 
follow-up study 6 years ago. The groups were equal for difference 
in levels of IL-6 (p=0.60) and TNF-α (p=0.72). They were also 
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equal for the McGill pain score (p=0.41), temperature difference 
(p=0.41), volume difference (p=0.48), and mobility (p=0.83). 
The two groups were only significantly different from each other 
for VAS pain (p=0.03). The characteristics and medication use of 
the 12 patients with CRPS1 in one extremity for 6 years (median) 
who were examined 3 times during the follow-up of their CRPS1 
are presented in Table 1. 
Table 1. Characteristics of the study population
Data are presented as the n or median (interquartile range).
Patient characteristic
Gender: male/female
Side:  right/left 
Cause: fracture/accident/surgery/sponta 
 neous
Age in years
Duration of CRPS1 in months
Disease related medication 
(number of patients)
 Non-steroid anti-inflammatory  
  drugs (NSAIDs)
 Opiates
 Anti-oxidants
 Vasodilators
 Muscle relaxants
 Anti-depressants
 Benzodiazepines
 Anti-epileticum
Value
3/9
6/6
6/2/4/0
T0
52 (48-56)
4 (3-14)
6
4
8
1
1
1
2
1
T1
54 (51-58)
35 (21-48)
1
2
1
0
0
1
0
0
T2
57 (54-62)
72 (59-86)
0
2
0
0
0
0
0
1
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Table 2. Levels of IL-6 and TNF-α in blister fluid obtained from the CRPS1 
and contralateral extremities at first measurement (T0), second measurement 
(T1) and third measurement (T2). Data are presented as mean (range).
* Wilcoxon signed-ranks test p<0.05 (CRPS1 vs contralateral).
The IL-6 and TNF-α levels in blister fluid at all time intervals are 
presented in Table 2. The differences in levels of IL-6 between 
both extremities did not significantly change at T1 compared to 
T0 (p=0.531) and at T2 compared to T0 (p=0.063). However, the 
differences in levels did significantly decrease at T2 compared to 
T1 (p=0.028). The differences in levels of TNF-α between both 
extremities did not significantly change at T1 compared to T0 
(p=0.892) and at T2 compared to T0 (p=0.153). The decrease in 
differences from T1 to T2 almost reached significance (p=0.064). 
At the T0 and T1 measurement, the difference in levels of IL-6 
and TNF-α between the CRPS1 side and the contralateral side in 
blister fluid were significantly different from 0. However, at the 
T2 measurement, no significant differences between the two sides 
were evident (Figure 1a and 1b) for the 12 CRPS1 patients. 
Also the signs and symptoms of impairment were measured at 
T0, T1 and T2 in terms of pain and differences in temperature, 
volume, and mobility between the CRPS1 and the contralateral 
extremities. The VAS pain did not significantly change during 
the course of the disease in these 12 patients (p=0.472). The 
McGill pain score improved significantly at T1 compared to T0 
(p=0.006), but pain was significantly worse at T2 compared to 
T1 (p=0.041). Furthermore, no significant improvement was 
seen at T2 as compared to T0 (p=0.567). The VAS pain and the 
McGill pain score significantly differed from 0 during all 6 years 
of follow-up (Fig. 2a and 2b).
 
                     
IL-6 
(pg/ml)
TNF-α 
(pg/ml)
CRPS1
116*  
(5-662)
66*
(1-359)
Contralateral
8 
(1-36)
31 
(1-258)
CRPS1
80*
(1-346)
56*
(3-176)
Contralateral
2
(0-5)
16 
(2-80)
CRPS1
22
(4-78)
38 
(9-81)
Contralateral
20
(3-61)
47
(10-142)
T0 T1 T2
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Figure 1a. 
Figure 1b.
Figure 1. Differences in levels of IL-6 and in TNF-α in blisterfluid between the 
CRPS1 and contralateral extremities over the course of CRPS1. Blister fluid 
was collected as described in Materials and Methods and IL-6 (panel a) and 
TNF-α  (panel b) levels (pg/ml) in the CRPS1 and the contralateral limbs were 
measured by ELISA. The data obtained from the same 12 patients at each time 
period are expressed as the difference in IL-6 or TNF-α levels between the two 
sides (log pg/ml).  Each time point shows the mean α the standard deviation. 
The p values represent the deviation from no difference (0).
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Figure 2a. 
Figure 2b. 
Figure 2c.  
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Figure 2d. 
Figure 2e. 
Figure 2. The assessment of pain over the course of CRPS1 disease as measured 
by the Visual Analogue Scale is shown in panel (a). Panel (b) shows the 
assessment of pain as measured by the McGill Pain Questionnaire. Panel (c), (d) 
and (e) respectively show the absolute differences in skin surface temperature, 
the absolute differences in volume, and the differences in AROM between the 
CRPS1 and contralateral sides in CRPS1 patients over the course of disease. 
The data obtained from the same 12 patients at the 3 points of measurement 
were collected as described in Materials and Methods and are expressed as 
the mean ± standard deviation. The p values represent the deviation from no 
difference (0).
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The absolute difference in temperature and volume between both 
sides did not change during the course of the disease (p=0.204 
and p=0.509 respectively). The difference between the CRPS1 
and contralateral side did vary significantly from 0 at all three 
moments of measurement for temperature and volume (Fig. 2c). 
Mobility improved significantly at T1 and T2 as compared to T0 
(p=0.002 for both), with no significant increase in AROM at T2 
compared to T1 (p=0.353). The difference in mobility between 
both sides was significantly different from 0 at T0 and T1, but no 
significant difference was found at T2 (Fig. 2e). 
No correlation was found between the differences in levels of the 
proinflammatory cytokines and the other disease-related param-
eters pain and differences between both extremities for temper-
ature, volume and mobility during the course of the disease.
The total use of disease related medication was divided in 8 
categories (see Table 1). The total number of patients using 
medication as well as the variety in types of medication decreased 
during the course of the disease. 
Discussion
In a six years follow-up study in 12 CRPS1 patients, we found 
a decrease in the extent of the differences in levels of TNF-α 
and IL-6 in blister fluid. After disease duration of 4 months (T0) 
and of 3 years (T1), the levels of these cytokines were signifi-
cantly higher in the CRPS1 extremity compared to the contral-
ateral extremity. However, after 6 years (T2) the differences in 
the cytokine levels between the two extremities were not signifi-
cantly different. In contrast, the difference in mobility between 
both sides was significantly improved after 6 years. Pain and the 
differences in temperature and volume were not significantly 
altered during the course of the disease. No correlation was found 
between the pro-inflammatory cytokines and the disease charac-
teristics.
Because TNF-α and IL-6 are proinflammatory cytokines, one 
might expect that these markers of inflammation would be 
directly related to the characteristics of inflammation: pain, 
temperature increase, edema, and loss of function. In this study 
the levels of TNF-α and IL-6 were diminished during the course 
of the disease, but no clear improvement of inflammatory signs 
was found. Most of the 12 patients still reported much pain. The 
VAS score did not change during the course of the disease, and 
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while the McGill Pain score improved at first, it worsened again 
at the third measurement. The absolute temperature difference 
tended to diminish during the course of the disease; however, this 
was not  significant. The volume difference also did not change 
significantly during the course of the disease. Only the AROM 
improved significantly after 6 years; the patients only described 
some stiffness of the joints. 
No improvement of the signs and symptoms of inflammation was 
found as described above, however after six years, a decline in the 
number of patients using medication that could counteract inflam-
mation has been observed, such as NSAIDs, opiates and anti-
oxidants. We concluded that the normalization of inflammatory 
mediators after six years was not affected through pharmaco-
logical intervention, but due to a diminution of disease activity.  
An explanation for a decrease in differences in the levels of TNF-α 
and IL-6 between both sides during the course of CRPS1 is a 
spreading of the disease from the CRPS1 side to the contralateral 
extremity. This spreading could also be explained by the fact that 
the levels in the CRPS1 side are increased during the course of 
the disease. However, the increased levels of the contralateral side 
measured 6 years after the initial event do not even come close 
to the high levels of TNF-α and IL-6 measured in the CRPS1 
side 4 months and 3 years after the initial event. Furthermore, the 
levels of IL-6 of both sides at T2 are within the normal range of 
the levels measured in blister fluid from healthy controls (mean 
16 pg/ml) [23]. These findings do not support the theory of 
spreading. Finally, one would expect that the differences between 
both sides in disease activity would decrease during the course of 
the disease when there is spreading. This is not confirmed in this 
follow-up study.
In the present study, in contrast with the diminished levels of the 
proinflammatory cytokines during the course of the disease, signs 
of inflammation were found in all three stages of the disease. In 
an earlier study, during the first two years of CRPS1, about half 
of the patients showed no inflammatory signs [24], but did fulfil 
the criteria of Bruehl [15]. Several other studies confirmed that 
observation, even describing a primarily cold CRPS1 [4, 10, 25, 
26]. 
An explanation for finding a temperature increase and decrease 
already at the onset of CRPS1, is that blood flow, and thus 
changes in skin temperature, are the result of not only afferent 
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mechanisms, such as local mediators, but also efferent mecha-
nisms. Disturbances in central temperature regulation could result 
in altered (local) temperature of the injured extremity [27-29]. 
Recently we found evidence that temperature changes also might 
be partly caused by the crosstalk in the vascular system between 
higher levels of cytokines and the nitric oxide/endothelin-1 (NO/
ET-1) balance [30, 31]. Furthermore, blood flow and tissue-blood 
distribution could be diminished, partly due to disuse of the 
extremity [13]. 
A possible explanation for finding edema and atrophy during all 
stages of the disease is that edema is not only affected by TNF-α 
and IL-6 but also by other inflammatory mediators such as calci-
tonin gene-related peptide (CGRP) and substance P (SP), and 
related mechanisms [32, 33].
No correlation was found between the differences in levels of 
the cytokines and pain and differences between both extrem-
ities for temperature, volume and AROM for all three times of 
measurement. In an earlier study, we found similar results [24]. 
Perhaps IL-6 and TNF-α are only partially responsible for the 
permanent damage in CRPS1, expressed as pain, and changes in 
temperature, volume, and mobility. Other mediators or a combi-
nation of mediators, such as nitric oxide [30] and/or amino acids 
[34, 35] or other mechanisms [7] may also play a role in the 
pathophysiology of CRPS1 and may explain in part the course of 
the disease. 
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Abstract
Various inflammatory mediators have been identified as potential 
contributors to complex regional pain syndrome type 1 (CRPS1), 
but these mediators do not entirely explain certain manifesta-
tions of the syndrome, such as pain. The objective of this study 
was to investigate the role of amino acids in the pathogenesis of 
CRPS1. We used HPLC to determine plasma concentrations of 
16 amino acids, especially those related to the NMDA receptor 
(e.g., glutamate and glycine) and nitric oxide synthesis (e.g., 
arginine and citrulline) in patients with CRPS1 (n = 64) and 
age- and sex-matched healthy controls (n = 51). Patients rated 
pain intensity (visual analog scale) and the subjective experience 
of pain intensity (McGill Pain Questionnaire). Psychological 
dysfunction was assessed using the SCL-90. Relative to controls, 
in CRPS1 patients’ plasma levels of glutamate, arginine, taurine 
and glycine were increased, and plasma levels of glutamine and 
the ratio of citrulline to arginine were decreased. Remarkably, in 
CRPS1 patients there was a highly significant inverse correlation 
between glutamine and glutamate, although the sum of molar 
concentrations of glutamate and glutamine remains unchanged. 
Subjective measures of pain and indicators of psychoneuroticism 
and emotional instability did not correlate with amino acid levels. 
This study shows for the first time a pronounced increase in amino 
acid levels in this chronic pain syndrome. The marked differences 
in glutamate, glutamine, glycine, taurine and arginine levels 
between patients and controls suggest the involvement of both the 
NDMA receptor and the endothelium-dependent arginine-nitric 
oxide system in CRPS1.
Introduction 
Complex regional pain syndrome type 1 (CRPS1) is a disease 
of severe chronic pain in an extremity; it usually develops after 
trauma or surgery. In addition to pain, CRPS1 is characterized by 
other sensory and autonomic, motor, and dystrophic signs and 
symptoms [1]. These include changes in skin surface temperature, 
edema, hypersensitivity, and allodynia. In the chronic phase of 
CRPS1, patients report continuous pain and temperature change 
in the affected extremity, an indication of perturbed blood tissue 
distribution. All signs are indicative of local neurogenic inflam-
mation [2, 3]. In most cases, CRPS1 leads to a dramatic loss of 
function and disability. The subsequent phases and related mecha-
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nisms underlying the disease are poorly understood. Therefore 
the availability of effective treatment is still missing. 
    
Inflammation
Some of the prominent signs and symptoms of CRPS1 (e.g., 
redness, increased skin temperature and edema) could be explained 
by formation of neuropeptides [2] or proinflammatory cytokines 
[4, 5]. CRPS1 may involve a process of central sensitization, 
which exacerbates pain, through neuroimmune activation of cells 
in the peripheral nervous system [6]. In general, standard pharma-
cological and interventional therapy successively provide insuffi-
cient suppression of the spread of CRPS1 from the distal part to the 
entire extremity [3]. Therefore, it is likely that other mechanisms, 
which result in the release of potent pain-related substances, are 
involved. In open trials, some patients with CRPS1 responded 
well to the N-methyl-D-aspartate (NMDA) receptor antagonist 
ketamine [7-10], providing indirect evidence for the involvement 
of specific amino acids (such as glutamate and glycine) in CRPS1. 
Also, activation of monocytes, macrophages, and mast cells after 
injury could lead to a pronounced increase in proinflammatory 
cytokines and chemokines in CRPS1 [4, 5]. 
Ischemia
Permanent damage to nerve endings can reduce both endothelium-
dependent dilatation and regional blood distribution [11]. Distur-
bance of the microcirculation causes ischemia, which elicits pain 
and inhibits oxidative phosphorylation. By virtue of the cellular 
structure of the microvessels, endothelial and smooth muscle 
cells are the first to confront the metabolic change. Recently, 
we demonstrated an imbalance between endothelium-derived 
endothelin-1 and nitric oxide (NO) in CRPS1 [12]. This could be 
due to activation of endothelial cells or smooth muscle cells by 
proinflammatory cytokines or to changes in levels of arginine.
Central effects
Continuous inflammation could result in nociceptor sensitization 
and/or increased release of substances modulating neurons and 
glia [6]. Recently it was found that glutamate is released into 
the cerebrospinal fluid of CRPS1 patients [13]. However, to our 
knowledge, plasma amino acid levels in CRSP1 have not previ-
ously been assessed.
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Based on the literature we hypothesize that in CRPS1 patients 
the amino acids which bind to the pain-related NMDA receptor 
(e.g., glutamate and glycine) would be increased, and that, due to 
endothelial dysfunction, the NO-related synthesis of the amino 
acids arginine and citrulline could be affected.
The aim of this study was therefore to investigate plasma concen-
trations of a number of amino acids in order to determine whether 
changes in the plasma levels of the hypothesized amino acids 
display some specificity for CRPS1. We compared absolute 
levels of amino acids between patients with CRPS1 and age- and 
sex-matched healthy controls, and assessed correlations with pain 
visual analog scores, McGill pain intensity, and quality of life 
factors.
Methods
The protocol was approved by the Medical Ethics Committee 
of the Erasmus Medical Center, Rotterdam (MEC no. 
1989.780/2001/24). All procedures were performed in accor-
dance with the Helsinki declaration. Written informed consent 
was obtained from all patients.
Subjects 
All CRPS1 patients were referred from the southwest Nether-
lands to the pain clinic of the Erasmus Medical Center. Sixty-four 
patients diagnosed with CRPS1 in one extremity were recruited. 
Most of the patients were in the early chronic phase of the disease, 
with a mean disease duration of 34.7 months. Diagnosis of the 
patients was established based on the medical history and the 
anamnesis to record the signs of the disease and based on physical 
examination to record the CRPS1-specific symptoms according 
to the criteria developed by Bruehl et al. [14]. Fifty-one age- and 
sex-matched healthy controls recruited from the employers of 
the Erasmus Medical Center, living in southwest Netherlands, 
also participated. Participant demographic characteristics are 
presented in Table 1.
Blood samples and amino acid determinations
EDTA blood samples (7 ml) were collected by venipuncture from 
patients and healthy controls. In order to detect local synthesis of 
amino acids, in each patient blood samples were obtained from 
the CRPS1 affected extremity and a contralateral extremity. For 
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Table 1 Demographic data and characteristics of the patients and healthy 
controls
Means ± SEM; healthy controls were age and sex matched in comparison with 
CRPS1 patients
the 50 patients with CRPS1 in the upper extremity, blood was 
obtained from the cubital vein of the CRPS1extremity and the 
contralateral upper extremity. For the 14 patients with CRPS1 in 
the lower extremity, blood was obtained from the femoral vein 
of the CRPS1 extremity and the cubital vein of the contralateral 
upper extremity. For the healthy controls, one blood sample was 
obtained from the cubital vein of an upper extremity.
Plasma was isolated by centrifugation at 2650 gmax for 10 min at 
20 °C, and samples were stored at -80 °C until assay. Plasma was 
deproteinized with 5-sulphosalicylic acid (6%, w/v) containing 
norvaline and homoserine as internal standards. Amino acids 
were assayed by high-performance liquid chromatography 
(HPLC) using automated precolumn derivatization with o-phthal-
dialdehyde and fluorescence detection [15]. The following amino 
Number of patients
 Males/females
Number of healthy controls
 Males/females    
Mean age (years)
 Patients
 Healthy controls
Localization of CRPS1 at diagnosis
 Upper extremity
 Lower extremity 
Mean time between onset of the disease and plasma 
sample taken for amino acids measurement (months)
Disease-related medication (number of patients used)
Non-steroid anti-inflammatory drugs (NSAIDs)
Opiates 
Anti-oxidants
Vasodilators
Muscle relaxants
Anti-depressants
Benzodiazepines                               
Value 
64
15/49
51
11/40
48  ± 1.6
48  ± 1.3
50
14
34.7  ± 5.1
29
21
25
20
6
10
6
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acids were determined: glutamate, glutamine, arginine, citrulline, 
serine, glycine, taurine, methionine, lysine, ornithine, isoleucine, 
leucine, valine, phenylalanine, tyrosine and tryptophan. The limit 
of detection depends on the amino acid in question, because of 
different fluorescence responses and differing peak shapes of the 
deriv¬atives. Typi¬cal values were 54 fmol for glutamate and 
167 fmol for serine. Concentrations of amino acids down to 0.5 
μmol/L in plasma can be measured accurately with our method. 
The interassay coefficient of variation was for all amino acids 
below 4%. 
Visual analogue scale, McGill Pain Questionnaire, and 
SCL-90
During patients’ visit to the pain clinic, pain intensity was deter-
mined using a visual analogue scale (VAS) [16] and the McGill 
Pain Questionnaire Dutch-Language Version (MPQ-DLV) (17). 
The VAS is measured in millimeters (0, no pain; 100, most intense 
pain). The MPQ-DLV score is calculated by counting the total 
number of words chosen (0-20) [17]. 
Patients completed the Dutch language version of the SCL-90 
[18], a multidimensional, self-report inventory comprising 90 
items measuring dimensions such as anxiety, agoraphobia, 
depression, somatization, inadequacy, sensitivity, hostility, and 
insomnia. The total score is a measure of psychoneuroticism and 
emotional instability.
Statistical analysis
Data were analyzed with SPSS for Windows, version 12.0.1. 
Variables are reported as the mean ± SEM. Group differences 
were assessed using the t-test for independent samples; we used 
the Bonferroni correction for multiple comparisons, resulting 
in an alpha-level of 0.003. Differences in plasma amino acid 
concentrations between CRPS1 and contralateral extremities were 
evaluated using the Wilcoxon paired samples test. Protection for 
multiple Correlations between age, sex, disease duration, pain, 
quality of life and amino acids were examined with Pearson’s 
correlation test. P-values were two-sided, and a p-value < 0.05 
was considered statistically significant.
Results
At diagnosis, CRPS1 was mostly localized to the upper extremity 
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(Table 1). In 13 patients, it was inappropriate to obtain blood from 
the affected extremity; therefore, blood was obtained from both 
the CRPS1 extremity and the contralateral side in 51 patients. For 
all amino acids measured, paired samples of the CRPS1 extremity 
and the contralateral extremity were highly correlated (r > 0.90 
and p < 0.001). An example is shown in Fig. 1.
Figure 1. Representative example of paired sample analysis of plasma amino 
acid concentrations (μmol/L). Plasma glutamate concentrations in samples 
obtained from the CRPS1 extremity and the contralateral extremity are shown 
(r = 0.96; p < 0.001). 
Based on these results, for further analysis and comparison to 
healthy controls, of whom only one sample was obtained from one 
upper extremity, for each amino acid the individual mean plasma 
value of the affected side and contralateral side was determined. 
Table 2 shows the mean values of 16 amino acids in plasma of all 
patients and those of the healthy controls. For a number of amino 
acids, the mean concentration was significantly different between 
patients and healthy controls. However, in terms of absolute 
change in μmol/L amino acid, the remarkable differences were 
for glutamate, glutamine, arginine, taurine, serine, and glycine 
(Fig. 2). 
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Table 2 Amino acid concentrations in plasma of CRPS1 patients and healthy 
controls
Concentrations in μmol/L.  * P<0.003
We investigated correlations between these six amino acids and 
found that there was a highly significant inverse correlation 
between glutamate and glutamine for patients (Fig. 3; r = - 0.79, 
p < 0.001), but not for healthy controls. 
Subgroup analysis was performed for disease-related medication 
(non-steroid anti-inflammatory drugs (NSAIDs), opiates, anti-ox-
idants, vasodilators, muscle relaxants, anti-depressants and benzo-
diazepines) and amino acids. No correlations were observed.
A weak but significant correlation was found between duration 
of CRPS1 (in months) and plasma arginine levels (r = 0.41; p = 
0.001). Furthermore, a slight but significant difference in plasma 
arginine levels was found between CRPS1 in the upper and lower 
extremity (178 ± 5.3 μmol/L and 148 ± 13 μmol/L, respectively; 
p = 0.015). The ratio of citrulline to arginine was significantly 
lower in CRPS1 patients versus healthy controls (0.203 ± 0.011 
versus 0.519 ± 0.023; p < 0.001). 
Amino acid
Glutamate
Glutamine
Arginine
Citrulline
Serine
Glycine
Taurine
Methionine
Lysine
Ornithine
Isoleucine
Leucine
Valine
Phenylalanine
Tyrosine
Tryptophan
CRPS1 patients (n=64)
mean SEM
 
270* 14.5
330* 14.9
171* 5.2
33 1.4
 
160* 3.0
267* 7.0
95* 4.9
15* 1.2
 
203 5.0
88 3.3
 
83 3.0
157 5.3
260 7.4
78* 1.8
68 2.4
51 1.2
Healthy controls (n=51)
mean SEM
 
47 2.8
559 11.9
71 3.1
35 1.2
 
111 2.8
216 5.9
42 1.1
31 0.9
 
185 5.0
86 3.2
 
82 3.8
147 4.4
285 8.2
62 1.4
70 2.2
50 1.6
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Figure 2. Mean absolute change in plasma amino acids in patients relative to 
healthy controls. 
Figure 3. Correlation between plasma levels of glutamate and glutamine. 
Levels were highly correlated in CRPS1 patients (upper panel; r = -0.79, p 
< 0.001), but they were not correlated in healthy controls (lower panel). gln: 
glutamine.
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The mean intensity of pain was moderate: the mean VAS score in 
CRPS1 patients was 48 ± 3.4 mm, and the McGill pain intensity 
rating was 11.7 ± 0.59. VAS and McGill questionnaire scores did 
not correlate with amino acid levels. Thus, as an example, there 
was no correlation between VAS scores and glutamate levels (r 
= -0.03 and p = 0.823) and McGill questionnaire and glutamate 
levels (r = 0.10 and p = 0.470).
The mean SCL-90 score was 140 ± 6.2, which is comparable to 
the score in a normal population, and in the same range as in 
previously studied CRPS1 patients [19]. The mean score did not 
correlate with amino acid levels. There was a slight but significant 
correlation between the SCL-90 score and VAS score (r = 0.37 
and p = 0.004) and between the SCL-90 score and the McGill 
pain intensity rating (r = 0.34 and p = 0.02).
Discussion
The main findings of this study are a pronounced increase in 
plasma levels of glutamate, arginine, glycine and taurine and a 
pronounced decrease in plasma glutamine in CRPS1 patients 
compared with age- and sex-matched healthy controls. No differ-
ences were observed between plasma samples drawn from the 
CRPS1 extremity and the contralateral extremity; paired samples 
were highly correlated. This indicates that changes in amino acid 
levels are not necessarily evoked at the site affected by CRPS1. 
We also observed a highly significant inverse correlation between 
glutamine and glutamate. The sum of molar concentrations of 
glutamate and glutamine remains unchanged suggesting altered 
interconversion of glutamate and glutamine. Glutamine is 
converted into glutamate by the enzyme glutaminase. Furthermore, 
it is known that glutamine is used for the synthesis of urea in the 
liver, for renal ammoniagenesis and for gluconeogenesis in both 
liver and kidney and as a major respiratory fuel for many cells [20]. 
In burn patients, however, in whom immunological function and 
wound healing are the most prominent mechanisms, only reduced 
levels of plasma glutamine have been found [21]. Although it is 
generally accepted that glutamate will not pass the blood-brain 
barrier, plasma concentrations of glutamate are correlated with 
those in cerebrospinal fluid of ischemic stroke patients [22].
Surprisingly, amino acid levels did not correlate with subjective 
parameters of pain and indicators of psychoneuroticism or 
emotional instability.
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Some amino acids are released in chronic, painful diseases, such 
as migraine. Apparently there are some similarities between the 
underlying mechanisms of CRPS1 and patients with migraine. 
Alam et al. [23] found that plasma glutamate, glutamine, and 
glycine levels were all elevated in patients with migraine compared 
to healthy controls (a mean  increase of approximately 200, 150 
and 280 μmol/L respectively; ranges comparable with our data), 
whereas there were no such differences for patients with tension 
headache [23]. In a recent study, plasma glutamate levels were 
found to be increased in migraine patients, particularly patients 
affected by migraine with aura, compared to healthy controls [24]. 
In a study of patients with chronic migraine, with and without 
fibromyalgia (assigned as pressure allodynia), glutamate levels 
were higher in patients with versus without fibromyalgia [25]. 
Plasma levels of glutamate, glutamine, glycine, and taurine were 
reported to be significantly increased in patients with depression 
compared to controls (a mean increase of approximately 35, 160, 
105 and 85 μmol/L respectively), and a positive correlation was 
found between glutamate levels and the rate of depression [26]. 
Psychological abnormalities have been described in CRPS patients 
[27]; both the chronicity of the disease and the continuous pain 
contribute to these phenomena. However, patients in the current 
study did not exhibit specific psychological dysfunction. There 
was no direct correlation between subsets of the SCL-90 and 
amino acid levels. This was also true for subjective measures of 
pain, pain VAS scores and McGill pain intensity. 
Glycine is a co-agonist of the NMDA receptor and known to 
modulate immune cell responses in which the inhibitory effects 
on macrophages could be important [28]. As noted earlier, some 
open trials suggest that the NMDA receptor antagonist ketamine 
suppresses neuropathic pain, which mainly manifests as allodynia 
and hyperalgesia [29]. Multi-day low-dose ketamine infusion 
for treatment of CRPS1 acts through antagonism of the NMDA 
receptor, resulting in a significant reduction of pain intensity 
and an improvement of mobility [8]. Also, ketamine reduces the 
capsaicin-evoked intensity and unpleasantness of mechanical 
hyperalgesia [30]. 
The increase in plasma arginine was not accompanied by a 
change in citrulline levels. In addition, the concentration of 
ornithine was not different between CPRS1 patients and controls. 
These observations point to reduced activity of one or more of 
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the NO synthase isoenzymes rather than changes in the activity 
of ornithine carbamoyltransferase, argininosuccinate synthase, or 
arginase. The higher plasma arginine levels in the patients may be 
partly due to reduced glutamine levels, because glutamine inhibits 
the generation of arginine in cultured endothelial cells [31]. 
Plasma arginine levels correlated with the duration of CRPS1 (in 
months), an indication that conversion of arginine to citrulline 
and NO is altered during the course of the disease. This could 
result in vasoconstriction, diminished tissue blood distribution, 
and spread of pain [12].
The citrulline/arginine ratio, regarded as an index of NO synthesis 
[32], was decreased in our CRPS1 patients. Although this decrease 
was due to a marked increase in plasma arginine, it is nevertheless 
probable that NO synthesis was decreased rather than increased, 
resulting in vasoconstriction of blood vessels in the CRPS1 
extremity. During the early chronic episode of the disease, most 
of our patients exhibited a cold extremity, indicative of vasocon-
striction [33]. This could also be due to increased levels of taurine, 
which were two-fold higher relative to controls. The release of 
taurine in various cell-damaging conditions, including ischemia 
and increased free radical production, have been shown [34]. 
Taurine in turn has antioxidative properties [35]. Very recently it 
has been shown that taurine could diminish neuropathic nocice-
ption, possibly through interaction with the glycine receptor [36]. 
It has been reported that taurine reduces cyclic GMP, which evokes 
vasodilation [37]. This suggests that application of a phosphodi-
esterase inhibitor would restore the cGMP-induced vasodilation 
and therefore could be beneficial in CRPS1. Another possibility is 
supplementation with glutamine, which not only was significantly 
reduced in our patients, but may also be beneficial for increasing 
NO synthase activity, theoretically resulting in greater conversion 
of arginine to NO [38]. However, only 1% of the total arginine 
flux is used for NO synthesis; therefore a change in the formation 
of the latter substance is very unlikely to affect arginine levels 
dramatically [39].
Analgesics and other medication used by the patients were not 
correlated with changes in the amino acid profile. Some limita-
tions of this study are the lack of information concerning nutri-
tional behaviour of CRPS1 patients in comparison with healthy 
controls. Furthermore, we failed to register body weight and 
length (resulting in the BMI) of all subjects. Nevertheless, in our 
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opinion the marked changes found in the CRPS1 group not only 
could be affected by these parameters. 
In conclusion, our descriptive study shows for the first time a 
pronounced increase in amino acid levels in this chronic pain 
syndrome. The marked differences in glutamate, glutamine, 
glycine, taurine and arginine levels between patients and healthy 
controls suggest the involvement of both the endothelium-
dependent arginine-nitric oxide system and the NDMA receptor 
in CRPS1. No proof, however, could be provided that the changes 
in plasma amino acids are causally related to the pathogenesis 
of CRPS1. After all, no correlations with measures of pain 
and indicators of psycho neuroticism and emotional instability 
were found. A randomized controlled trial, in which the effects 
of ketamine administration on both disease activity in CRPS1 
patients and amino acids is being studied, should confirm the 
involvement of specific amino acids in this disease.
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Abstract 
In patients with complex regional pain syndrome type 1 
(CRPS1), some improvement can be achieved by the adminis-
tration of ketanserin, a 5-HT2A receptor antagonist.  Our aim 
was to measure plasma levels of serotonin (5-HT) during CRPS1 
and correlate these levels with disease characteristics. Plasma 
5-HT was measured in 35 patients with CRPS1 for 3 years and 
compared with those of 35 age-matched healthy controls. The 
plasma 5-HT levels were 411 ± 263 nmol/l and 29 ± 18 nmol/l, 
respectively (P < 0.001). No correlations with disease charac-
teristics were observed. The markedly elevated levels of plasma 
5-HT in CRPS1 patients suggest a role for 5-HT during the course 
of this disease. However, because of the lack of correlations with 
distinct disease characteristics, 5-HT is probably one of a number 
of mediators in CRPS1.
Introduction
Complex regional pain syndrome type 1 (CRPS1) is a compli-
cation that follows trauma or surgery in an extremity, leading to 
a dramatic loss of function, disability, and chronic pain. Thera-
peutic options are limited and insufficient to provoke complete 
recovery [1-4]. In an animal model, prolonged disturbance of the 
microcirculation by ischemia/reperfusion causes pain and other 
signs of CRPS1, such as oedema and changes in skin temperature 
[5]. Similar signs have been observed after cardiac catheterization 
via the radial artery [6, 7].
In blood vessels, serotonin (5-hydroxy-tryptamine; 5-HT) 
evokes vasoconstriction through activation of the 5-HT2A 
receptor. Important actions and functions of 5-HT are: i) vascular 
constriction and contraction of other smooth muscles; ii) increased 
micro vascular permeability; iii) induction of blood platelet aggre-
gation; iv) stimulation of peripheral nociceptive nerve endings 
and v) excitation/inhibition of neurons in the central nervous 
system. Clinical conditions associated with disturbed 5-HT 
function include migraine, carcinoid syndrome, mood disorders, 
and anxiety [8, 9].
Specific 5-HT2A receptor antagonism by ketanserin results in a 
pronounced vasodilatation, which was demonstrated in CRPS1 
patients two decades ago. Two case reports indicated that ketan-
serin was an effective vasodilator in sympathetic dystrophy or 
causalgia (currently known as CRPS1) [10, 11], and a double-
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blind placebo-controlled crossover trial of 16 patients with 
chronic peripheral burning pain demonstrated the beneficial 
effect of ketanserin [12]. Based on that report, ketanserin is also 
recommended for clinical use in chronic CRPS1 [13]. However, 
no studies investigating 5-HT levels in the CRPS1 affected limb 
or in the circulation that would justify this type of pharmaceutical 
intervention have been performed [14].
Our aim was to investigate whether CRPS1 patients had detectable 
increases in plasma 5-HT concentrations during the course of the 
disease. Some patients with CRPS1 exhibit besides the described 
physical limitations also psychological dysfunction [15], and this 
phenomenon could be associated with increased 5-HT [16]. The 
co-occurrence of increased 5-HT with chronic pain suggests that 
5-HT could be a common causative factor in chronic pain and 
psychological dysfunction [17]. Therefore, we also compared 
plasma 5-HT levels with pain, disease activity (skin surface 
temperature, oedema and mobility) and a self-report inventory.
 
Methods
The protocol was approved by the Medical Ethics Committee 
of the Erasmus MC Rotterdam (MEC no. 1989.780/2001/24) 
and written informed patient consent was obtained. Guidelines 
according to the Declaration of Helsinki (amended version of 
2002) and Good Clinical Practice (ICH/GCP version 1996) 
were followed. Data collection and calculations were performed 
according to guidelines for registration of personal data.
Subjects 
A total of 35 patients diagnosed as having CRPS1 in one extremity 
according to the criteria of Bruehl [18] were recruited for this 
study.
A group of 35 age-matched healthy controls were asked to give 
blood for plasma 5-HT analysis. Demographic data and charac-
teristics of the patients and controls are presented in Table 1, 
including any disease-related medication. None of the patients 
used ketanserin.
Blood samples
EDTA blood samples (7 ml) were collected from the patients and 
healthy controls. In 29 patients with CRPS1 in the upper extremity, 
blood was obtained from both the CRPS1 and the contralateral 
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extremity by venapuncture. In 6 patients with CRPS1 in the 
lower extremity, blood was drawn from the CRPS1 extremity, 
and a control sample taken from the contralateral upper extremity 
by venapuncture.  For the healthy controls, one sample of blood 
was drawn from an upper extremity by venapuncture. Blood was 
centrifuged at 2650×gmax for 10 min at 20°C and plasma was 
stored at –80°C until assay. 
Plasma serotonin determinations 
Measurement of plasma 5-HT concentration, and its break-down 
product 5-hydroxyindoleacetic acid (5-HIAA), was performed 
using reversed-phase HPLC method according to Bax et al. [19]. 
The detection limit for both compounds was approximately 3 
fmol at a signal to noise ratio of 3. The mean recoveries (± SD) 
of 5-HT and 5-HIAA added to the platelet poor plasma (PPP) 
samples were 95 ± 7% (n = 76) and 72 ± 8% (n = 35), respec-
tively.
Table 1 Demographic data and characteristics of the patients and healthy 
controls
Means ± SD; healthy controls were age matched with CRPS1 patients
Number of patients
              Males/females
Number of healthy controls
              Males/females                                                                            
Mean age (years)
              Patients
              Healthy controls
Localization of CRPS1 at diagnosis
              Upper extremity
              Lower extremity  
Mean time between onset of the disease and plasma sample 
taken for serotonin measurement (months) 
Disease-related medication (number of patients used)
 Non-steroid anti-inflammatory drugs (NSAIDs)
 Opiates 
 Anti-oxidants
 Vasodilators
 Muscle relaxants
 Anti-depressants
 Benzodiazepines
35
9/26
35
20/15
48  ± 12
48  ± 6.1
29
6
36  ± 41
12
4
13
3
1
2
4
76
76
Pain measurements
The maximal intensity of disease-related pain during the last 24 
hrs was determined using a visual analogue scale (VAS) [20, 
21] and the McGill pain questionnaire Dutch-Language Version 
(MPQ-DLV) [22]. The VAS is measured in millimetres (0-100, no 
pain to most intensive pain), and the MPQ-DLV score is measured 
by counting the total number of words chosen (0-20).  
Measurements of disease activity
1. Skin temperature measurements
Skin surface temperature also reflects blood tissue distribution. 
It is generally accepted that vasoconstriction or vasodilatation 
respectively leads to cold or warm extremities [1]. 
We measured skin temperature on the dorsal aspect of the hand 
or foot in a matrix of five points using an infrared tympanic 
probe thermometer (First Temp Genius®; Sherwood Medical 
Crawley, Sussex, UK) [23], and calculated the difference in 
mean temperature between the CRPS1 and the contralateral 
extremity. 
2.  Determination of oedema
We measured differences in the volume (in g) of the CRPS1 and 
contralateral extremities using a volumeter, which measures 
the amount of water displaced by the immersion of a body part 
[24].
3. Determination of mobility
We assessed mobility in the upper and lower extremity, by 
measuring the active range of motion (AROM) according to 
the American Society of Hand Therapists clinical assessment 
recommendations [25-27]. The AROM on the CRPS1 
extremity was multiplied by 100 and divided by the AROM on 
the contralateral extremity, resulting in percentage of normal 
mobility (100%).
 
Self-report inventory
Patients completed the Dutch-Language Version of the SCL-90 
[28]. The SCL-90 is a multidimensional, self-report inventory 
composed of 90 items that measures dimensions such as anxiety, 
agoraphobia, depression, somatization, inadequacy, sensitivity, 
hostility, and insomnia. The total score (between 90 and 450) is a 
measure of psychoneuroticism or emotional instability. 
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Statistical analysis
Data were analyzed with SPSS for Windows, version 12.0. The 
one-sample Kolmogorov-Smirnov test was used to determine 
whether or not the sample data were consistent with the normal 
distribution function. Data of temperature difference, volume 
difference, AROM, VAS pain, McGill pain, SCL-90, and the 
plasma 5-HT concentration were reported as mean ± SD. Between 
subjects, differences in plasma 5-HT concentrations between 
extremities were analyzed using the Wilcoxon signed-ranks test, 
and the correlation between parameters was calculated using the 
Pearson’s correlation coefficient. Differences in plasma 5-HT 
between patients and controls were tested by the Mann-Whitney 
test. The alpha of the tests was set at the traditional 0.05 level.
Results
5-HT
Plasma 5-HT levels in CRPS1 affected extremities (491 ± 280 
nmol/l) and the contralateral extremities (433 ± 260 nmol/l) were 
in the same range and correlated well with one other (r = 0.97; 
P < 0.001). However, we observed a marked difference between 
the plasma 5-HT levels of healthy controls and patients (Table 2), 
both in CRPS1-hands (441 ± 250 nmol/l; n = 29) and CRPS1 feet 
(265 ± 300 nmol/l; n = 6) in comparison with healthy controls. No 
differences were observed between males (390 ± 255 nmol/l; n = 
9) and females (418 ± 270 nmol/l; n = 26). Plasma 5-HT levels 
were not correlated with disease duration (correlation coefficient 
0.152, P-value 0.384). 5-HIAA was slightly and significantly 
decreased in CRPS1 patients (Table 2). Again, no differences 
were observed between males (26 ± 15 nmol/l; n = 6) and females 
(25 ± 10 nmol/l; n = 17). 
Table 2. Plasma 5-HT and 5-HIAA concentrations in CRPS1 patients and 
healthy controls
5-HT    (nmol/l)
5-HIAA   (nmol/l)
CRPS1 patients 
(n = 35)
     mean SD
      411 263 
       26 11
Healthy controls 
(n = 35)
      mean SD
        29 18
        41 9
P-value
< 0.001
< 0.001
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Pain
The mean VAS pain in this patient group (n=35) was 54 ± 28 
mm on a scale of 0-100 mm, whereas the McGill pain intensity 
(measured in n=26) was 12 ± 5 words out of 20 possible chosen 
words. Neither VAS pain nor McGill pain intensity correlated 
with plasma 5-HT (Table 3). Figure 1A and 1B show the distri-
bution of plasma 5-HT concentrations plotted against VAS pain 
and McGill pain intensity. 
Objective disease activity parameters and plasma 5-HT correla-
tions
Functional disease parameters have been measured effectively in 
a proportion of the patients. The temperature difference (n=29), 
the volume difference (n=22) and the AROM (n=22) did not 
correlate with plasma 5-HT levels (Table 3 and Figures 1C, 1D 
and 1E respectively). 
Self-report inventory
The total score of the SCL-90 (n=35) as a measure of psycho 
neuroticism or emotional instability in this group of patients was 
145 ± 50, which is not significantly increased in comparison with 
earlier published total scores from a normal population, and is 
in the same range as the CRPS1 patients from that study [15]. 
Sub-scale scores and the total score did not correlate with plasma 
5-HT levels (Table 3 and Figure 1F).
Table 3. Correlations between plasma 5-HT and other outcome measures
plasma 5-HT and:
VAS pain
McGill pain questionnaire
temperature difference
volume difference
mobility (AROM)
SCL-90 questionnaire
Correlation
coefficient
- 0.14
- 0.12
- 0.28
  0.39
- 0.38
- 0.32
P-value
0.429
0.547
0.145
0.073
0.088
0.079
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Figure 1A Figure 1B
Figure 1C Figure 1D 
Figure 1E Figure 1F
Figure 1. Distribution graphs of plasma 5-HT and VAS pain (A), plasma 5-HT 
and McGill pain questionnaire (B), plasma 5-HT and temperature difference 
(C), plasma 5-HT and volume difference (D), plasma 5-HT and AROM (E) and 
plasma 5-HT and SCL-90 questionnaire (F).
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Discussion
Our results show that plasma 5-HT concentrations are an order of 
magnitude higher in CRPS1 patients than in an age-matched (not 
gender), healthy control group. However, we detected no signif-
icant correlation between 5-HT levels and pain, disease activity, 
and the results of a self-reported inventory. 
The marked high 5-HT levels in platelet poor plasma (PPP) from 
CRPS1 patients are in the range normally found for platelet rich 
plasma (PRP). Platelets are considered to be the most important 
source of 5-HT in blood. So far no data have been presented 
regarding such high plasma 5-HT levels associated with a disease 
state. The simultaneously measured 5-HIAA plasma levels, which 
are in the normal range and even diminished in the CRPS1 patients, 
suggests a diminished breakdown of 5-HT in these patients.
The role of 5-HT in the course of CRPS1 remains unknown. Is 
5-HT only one of a number of mediators formed in a cascade of 
processes, or should it be considered as one of a number of key 
mediators in the cascade of consecutive processes? In the search 
for other key mediators of the processes that follow the initial 
traumatic event, several bioactive substances have been suggested 
and investigated. Neuropeptides released after damage to nerve 
endings initiate the release of a cascade of vasoactive mediators 
[29]. In patients who have recently developed CRPS1, increased 
pro-inflammatory cytokines were found to be increased in skin 
blister fluid taken from the CRPS1 extremity in comparison with 
the contralateral extremity [30, 31]. After two years, skin blister 
fluid cytokine levels are still increased [32]; however, during the 
course of the disease a pronounced decline in cytokine levels is 
observed [33]. Other vasoactive mediators, such as nitric oxide 
[34] and presumably 5-HT, could play a role in the cell-cell inter-
action and activation of other mediators. 
Based on the primary effects of 5-HT, in CRPS1 patients 
ischemia resulting in pain would be expected; furthermore, a 
diminished mobility, changing temperature and volume of the 
affected extremity could occur. Besides centrally affected pain 
perception, psychological dysfunction (depression) could have 
been developed. In patients with psychological dysfunction, mean 
plasma 5-HT levels in a range from 33 to 62 nmol/l have been 
reported; however, in some patients plasma 5-HT levels reached 
200-250 nmol/l, similar to our observations [35]. In a recent 
study, plasma 5-HT levels of psychiatric patients and controls 
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were found to be 78 ± 58 nmol/l and 33 ± 38 nmol/l, respectively. 
Again, some individual patients showed levels of >150 nmol/l 
[36, 37].  
From the pharmaceutical point of view, inhibition of 5-HT release 
from blood platelets and antagonizing the 5-HT2A receptor 
could counteract vasoactive effects associated with CRPS1 and 
promote recovery. This phenomenon has not been observed with 
therapies other than ketanserin. A beneficial effect of ketanserin 
on chronic peripheral burning pain has been suggested [12]. 
Furthermore, peripheral 5-HT2A receptor antagonism has been 
shown to attenuate primary thermal hyperalgesia and secondary 
mechanical allodynia following thermal injury [37]. However, 
this allodynia suppressing effect was attributed to the addition 
of L-carnitine, which affects ischemia and oxygen transport in 
the tissues, resulting in diminished pain intensity [38, 39]. In 
open studies, a number of CRPS1 patients have been treated with 
both ketanserin and L-carnitine [40]. That study suggests that 
pre-treatment with ketanserin is necessary to obtain the beneficial 
effects of L-carnitine. Alternatively, treating CRPS1 patients with 
NO donors could improve tissue blood distribution evoked by 
vasodilatation through increased cGMP levels [34]. Moreover, 
NO has shown to inhibit platelet 5-HT release [41]. Treatment 
with the antidepressant fluoxetine was associated with a signif-
icant decline in plasma 5-HT levels [42]. Until now, however, 
in CRPS1 patients only increased levels of catecholamines were 
associated with psychological dysfunction [43]. The role of 5-HT 
in psychological dysfunction [44] in CRPS1 patients still has to 
be confirmed. 
In conclusion, the markedly elevated plasma 5-HT concentra-
tions suggest a role for 5-HT in patients with CRPS1. However, 
because of the lack of correlations with distinct disease charac-
teristics, 5-HT is probably one of a number of mediators in the 
cascade of consecutive processes that occur in the course of this 
painful and debilitating disease. 
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Abstract
Inflammatory processes are known to be involved at least in the 
early phase of complex regional pain syndrome type 1 (CRPS1). 
Blister fluid obtained from the involved extremities displayed 
increased amounts of pro-inflammatory cytokines IL-6 and 
TNFα compared with the non-involved extremities. The aim 
was to investigate the involvement of mediators by measurement 
of several other cytokines using new detection techniques that 
enable multiple cytokine measurement in small samples. The use 
of a multiplex-25 bead array cytokine assay and LuminexTM 
technology enabled simultaneous measurement of representative 
1) pro-inflammatory cytokines such as GM-CSF, IL-1β, IL-1RA, 
IL-6, IL-8 and TNF-α; 2) Th1/Th2 distinguishing cytokines 
IFN-γ, IL-2, IL-2R, IL-4, IL-5 and IL-10; 3) non-specific acting 
cytokines IFN-α, IL-7, IL-12p40/p70, IL-13, IL-15 and IL-17; and 
4) chemokines Eotaxin, IP-10, MCP-1, MIP-1α, MIP-1β, MIG 
and RANTES. Although minimal detection levels are significantly 
higher in the bead array system than those in common ELISA 
assays, in blister fluid IL-1RA, IL-6, IL-8, TNF-α, IL-12p40/p70, 
MCP-1 and MIP-1β were detectable and increased in CRPS1 
affected extremities. Levels of IL-6 and TNF-α simultaneously 
measured by ELISA (Sanquin Compact kit) and by multiplex-25 
bead array assay (Biosource) were highly correlated (r = 0.85, P < 
0.001 for IL-6 and r = 0.88, P < 0.001 for TNF-α). Furthermore, 
IP-10 and eotaxin were detectable but diminished in CRPS1, 
whereas detectable amounts of IL-10 were similar in involved 
and non-involved extremities. In conclusion, multiplex bead 
array assays are useful systems to establish the involvement of 
cytokines in inflammatory processes by measurements in blister 
fluids of CRPS1. Ten representative cytokines were detectable. 
However, detection levels and amounts measured are at least 3 
times higher in the multiplex-25 array assay than in the ELISA 
assays used simultaneously for the measurement of cytokines.
Introduction
Complex regional pain syndrome type 1 (CRPS1), also known 
as reflex sympathetic dystrophy (RSD), is a debilitating painful 
disease in an extremity that is characterised by signs of allodynia 
and hyperalgesia, as well as vasomotor, sudomotor and motor 
trophic signs and symptoms. In general the disease persists in 
one extremity [1, 2]. The diagnosis of CRPS1 is mainly based 
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on clinical observation [3, 4], for which international research 
criteria have been determined [5]. Although some patients develop 
CRPS1 after an inciting event (trauma or surgery in the hand, foot 
or knee), the origin of this invalidating disease remains unknown. 
Subgroups of CRPS1 patients are described in whom either 
vasomotor signs, neuropathic pain or all signs of inflammation 
are prominent factors [6]. Studies on the underlying mechanisms 
of this disease have ranged from the effects of physiotherapy to 
pharmaceutical intervention and from biological active mediators 
to genetic mapping. During the initial stage of the disease 
most symptoms, such as oedema, redness, loss of function and 
temperature changes [7], suggest a local inflammatory process 
[8]. Therefore we subsequently investigated the involvement of 
inflammatory mediators during the initial stage of this disease and 
showed that the cytokines interleukin-6 (IL-6) and tumour necrosis 
factor α (TNF-α) were significantly increased in the affected hand 
or foot [9], which was confirmed by other markers of inflam-
mation [10]. Most treatments of CRPS1 are not evidence based. 
The patient-dependent choice of either physical therapy, pharma-
ceutical intervention or unconventional alternative medicine is 
still a matter of debate [8, 11]. Targeted treatment with anti-TNF 
(Infliximab) seems, however, to be successful in patients with 
confirmed signs of inflammation [12].   
In all our recent studies, skin blister fluids showed elevated 
amounts of IL-6 and TNF-α as a measure of local inflammation 
intensity. Due to the limited amount of fluid, however, in the same 
sample we were only able to measure 2 or 3 different mediators 
separately. Therefore the present study aimed to confirm the 
involvement of inflammatory processes underlying CRPS1 by 
measuring a large variety of cytokines simultaneously in the same 
small blister fluid sample. 
Until now commercially available ELISA kits are used to measure 
levels of cytokines in biological samples. Most of these kits 
require a two-fold diluted sample volume of 100 μl. Therefore, 
to examine a number of different classes of cytokines, volumes 
of more than a few hundred µl should be available, otherwise 
dilutions need to be made. However, this process of dilution could 
result in values that are below the detectable standard. The simul-
taneous measurement of a number of cytokines in a single sample 
using a new developed microbead-based flow cytometry system 
(LuminexTM), enables to detect of cytokines in small volume 
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samples of human biological material [13]. 
Successful measurement of six Th1/Th2 cell distinguishing 
cytokines (interferon-γ (IFN-γ), TNF-α, IL-2, IL-4, IL-5 and 
IL-10) have been reported in a single sample of human tears 
obtained from allergic patients [14, 15], and in plasma from 
children with neonatal sepsis; in these newborn infants, in the 
same samples the contribution of inflammatory cytokines (IL-1β, 
IL-6, IL-8, IL-10, IL-12 and TNF-α) was also evaluated [16]. This 
so-called inflammation panel was also used for the simultaneous 
measurement of cytokines in tracheal aspirates after mechanical 
ventilation [17].
Here we report on the simultaneous detection of 25 cytokines in 
blister fluids obtained from both the involved and the non-involved 
(contra lateral) extremities of CRPS1 patients. This is the first 
study in which such a large number of inflammatory cytokines, 
Th1/Th2 distinguishing cytokines and chemokines have been 
investigated in human skin blister fluids. 
Methods and materials
Patients and blister fluids
For this study 22 patients (4 male, 18 female; mean age 52 ± 8.2 
(SD) years) were selected, with a mean duration of the disease of 
2.75 ± 1.25 (SD) years, all being in the intermediate phase. During 
CRPS1 we in general distinguish four different disease phases. 
Stage I is defined as the warm or hypertrophic phase, stage II is 
defined as the intermediate phase, stage III is defined as the cold 
or early chronic phase, and at last in stage IV the definite chronic 
phase corresponds to atrophic signs, dystonie, and per definition 
stabilization of the disease or, in rare instances, to healing [8-12, 
18].
All 22 patients were characterized using the impairment sum score 
(ISS, according to Oerlemans et al [7].). At the time of the study 
this was 38 ± 16.6 (SD) on a scale of 0-100, indicating a medium 
disease activity. This score was calculated based on differences 
in skin surface temperature, volume of oedema, quantity of pain 
(Visual Analogue Scale), intensity of pain (McGill pain question-
naire) and motor function (as Active Range of Motion). 
Blisters were induced by means of a suction method [9, 10]. 
A 3-hole (5 mm diameter per hole) skin suction chamber was 
positioned on the skin of the upper extremity, on the dorsal side 
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of the involved hand and the flexor side of the non-involved 
forearm.
A vacuum of 300 mm Hg negative pressure was applied with 
an Atmoforte 350A aspirator pump (ATMOS Medizintechnik, 
Lenzkirch, Germany), which was reduced after 15 minutes to 250 
mm Hg and again, 15 minutes later, reduced to 200 mm Hg. This 
negative pressure was maintained until blisters containing suffi-
cient fluid had been developed, but not longer than 2.5 hours. The 
contents of the blisters were punctured and pooled from each side 
into a 1.5 ml Eppendorff conical polypropylene tube and centri-
fuged for 5 minutes at 1600 xg. The mean recovery of superna-
tants from control blisters was 173 ± 21 (± SEM) μl fluid, and 168 
± 17 μl blister fluid from the CRPS1 side. All samples were stored 
in 1 ml conical polypropylene tubes at –80 °C until analysis [9].
In these blister fluid samples IL-6 and TNF-α were analyzed 
separately by ELISA and a set of 25 cytokines were analyzed simul-
taneously using the LuminexTM system and the Multiplex-25 
array assay from Biosource.
Enzyme-Linked Immunosorbent Assays
Blister samples were diluted 4-fold in appropriate calibrator 
diluent assay buffer for the direct measurement of cytokines. 
Cytokine assays were performed following the manufacturers 
protocol (Pelikine™ human ELISA compact kits for IL-6 (M1906) 
and TNF-α (M1920), Sanquin, Amsterdam, The Netherlands). 
The standard curve ranges and mean calculated zero signal plus 
3 SD for IL-6 were 0-450 pg/ml and 0.2 pg/ml, respectively; 
and for TNF-α 0-1000 pg/ml and 1 pg/ml, respectively. The 
requested solutions were provided with the ELISA compact kits 
and additional toolkits (Pelikine-ToolTM set (M1980), Sanquin, 
Amsterdam, The Netherlands). 
In brief, the ELISA procedure (performed at room temperature) 
was as follows: The wells of a 96-wells plate were pre-coated 
overnight with 100 µl of coating antibody, diluted 1:100 with 
coating buffer (0.1 M carbonate/bicarbonate). Thereafter the wells 
were washed 5 times with 400 µl of phosphate buffered saline 
(PBS) containing 0.005% TWEEN and then blocked with 200 µl 
of blocking buffer (1:20 diluted in PBS) for 1 hour on a shaker. 
After washing the plate five times with washing buffer, 100 µl of 
unknown blister fluid samples (diluted 1:4 in assay dilution buffer) 
or standards were pipetted into the wells. The plate was incubated 
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for 1 hour on a shaker. After washing the plate five times with 
washing buffer, 100 µl of biotinylated antibody (diluted 1:100 in 
assay dilution buffer) was pipetted into the wells and incubated 
1 hour on the shaker. After washing the plate, the wells were 
incubated 30 minutes on a shaker with 100 µl of streptavidin-HRP 
conjugate (diluted 1:10,000 in assay dilution buffer). Thereafter 
the plate was washed for the last time with washing buffer and 
incubated with 100 µl of tetramethylbenzidine substrate solution. 
The reaction was stopped after 30 minutes with 100 µl of stop 
solution (1.8 M2SO4). The absorbance per well was measured at 
450 nm with a Medgenix ELISA reader. Sample concentrations 
were calculated using the appropriate standard calibration lines 
and the Softmax® software of the reader.
Multiplex–25 bead array assay
The human Cytokine multiplex-25 bead array assay kit for 
LuminexTM was purchased from Biosource (Nivelles, Belgium). 
This kit comprises all components necessary for the whole assay 
procedure, to be fulfilled within approximately 5 hours hands-on 
time. 
The following cytokines could be measured: 
-Inflammatory panel: GM-CSF (granulocyte, macrophage–
colony stimulating factor), IL-1β, IL-1RA (interleukin-1 
Receptor Antagonist), IL-6, IL-8, TNF-α; 
- Th1/Th2 panel: IFN-γ, IL-2, IL-2R, IL-4, IL-5, IL-10; 
- Cytokine II panel: IFN-α, IL-7, IL-12p40/p70, IL-13, IL-15, 
IL-17; 
- Chemokine panel: Eotaxin, IP-10 (interferon-γ inducing protein, 
10 kDa), MCP-1 (monocyte chemotactic protein), MIP-1α 
(macrophage inflammatory protein) , MIP-1β, MIG (monokine 
induced by  γ-interferon), RANTES (Regulated upon Activation 
Normal T cell Expressed and Secreted).
Standard curves for each cytokine (in duplicate) were generated 
by using the reference cytokine concentrations supplied in this 
kit. Blister samples were diluted 4-fold in appropriate assay 
diluent. The assay was performed in a 96-well filter plate, using 
all the assay components provided in the kit. All incubation steps 
were performed at room temperature and in the dark to protect the 
beads from light. 
In brief, the following procedure was performed: Firstly, the filter 
plate was pre-wetted with 200 μl of working washing solution 
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and then this solution was aspirated from the wells using a 
vacuum manifold. The beads (25 μl) were pipetted into each well 
and thereafter the filter plate wells were washed two times with 
washing buffer using the vacuum manifold. Incubation buffer 
(50 μl) and 1:4 diluted blister fluid samples or standards (50 
μl) were pipetted into the wells and incubated for 2 hours with 
the beads. Thereafter the wells were washed using the vacuum 
manifold and detector antibody conjugated to biotin (diluted 
1:10 with biotin diluent) was added. After incubation for 1 
hour, beads were washed again followed by an incubation of 30 
minutes with streptavidin conjugated to the fluorescent protein, 
R-Phycoerythrin (streptavidin-RPE, diluted 1:10). After washing 
to remove the unbound streptavidin-RPE, the beads (minimum 
of 50 beads per cytokine) were analysed in the LuminexTM 
100 instrument (Applied Cytometry Systems, Dinnington, UK), 
which monitored the spectral properties of the beads while simul-
taneously measuring the amount of fluorescence associated with 
R-phycoerythrin. Raw data (mean fluorescence intensity, MFI) 
were analyzed using StarStationTM software (Applied Cytometric 
Systems, Dinnington, UK). 
Statistical Analysis
All cytokines showed a skewed distribution. Comparison of paired 
samples (CRPS1 versus non-involved extremity) was performed 
with the paired t-test after logarithmic transformation of the data 
obtained from measurements in blister fluids. In case of values 
below the detection limit, the outcome was set at the detection 
limit and the paired sample t-test with adjustment for these left-
censored values, was performed using STATA software (CNREG 
procedure). The same method was used to assess the assumed 
linear relation shown in Figure 1. Correlation coefficients were 
determined by the Spearman’s test for untransformed data. 
Results
To our knowledge we are the only clinical investigators reporting 
on cytokine levels in blister fluids obtained from CRPS1 patients 
[9, 10, 19]. Therefore we searched for data obtained from artificial 
blisters in immunological skin diseases in order to compare 
detection ranges (Table 1).
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ELISA
Both IL-6 and TNF-α were measured in blister fluid samples 
of 22 CRPS1 patients, obtained from both the involved and the 
non-involved extremity. Standards were measured in duplicate 
for 8 data points including a zero standard. Standard curves were 
plotted through four parameter logistic curve fitting. R-squared 
values were 0.999 and 1.00, respectively. Calculated levels are 
presented in Table 2a. Because cytokines displayed a not normally 
distributed set of data, the median and the ranges are presented. 
Interleukin-6 and TNF-α were significantly increased at the 
CRPS1 side (paired sample test). 
Table 2a: Cytokine levels in blister fluids from 22 patients with complex 
regional pain syndrome measured by ELISA
Multiplex
Twenty-five cytokines were measured in the same blister fluid 
samples of the 22 CRPS1 patients as indicated in the previous 
section ‘ELISA’. Cytokine-specific single beads (25 different 
bead populations) were identified through sequential gating on 
Doublet Discriminator signal and intrinsic bead dye (red vs. 
infra-red) excluding bead aggregates and debris. The amount of 
cytokine was measured as mean fluorescence intensity (MFI) of 
the streptavidin-RPE signal on the outside of the beads from a 
minimum of 50 beads per cytokine. Standards were measured in 
duplicate for 9 data points including a zero standard. 
Standard curves were plotted through four or five parameter 
logistic curve fitting. All R-squared values were between 0.99 and 
1.00, except for IL-7 (0.968). 
In blister fluid from the ‘inflammatory panel’ IL-1RA, IL-6, 
IL-8 and TNF-α were detectable, from the ‘cytokine II panel’ 
IL-12p40 was detectable and from the ‘chemokine panel’ MCP-1 
and MIP-1β were detectable and all were increased in CRPS1 
affected extremities. 
ELISA
Inflammatory panel
IL-6
TNF-α
lowest detectable 
level (pg/ml)
0.2
0.5
levels in blister fluid median (range) in pg/ml
non-involved       CRPS1
2.7  (≤ 0.8–191) 38 (≤ 0.8–346)
10.3  (2.1-315) 48  (2.8-381)
P-value
0.002
0.006
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Table 2b: Cytokine levels in blister fluids from 22 patients with complex 
regional pain syndrome measured by multiplex-25 bead array assay
Blister fluids were diluted 4-fold in matrix buffer.
Lowest detectable level: lowest detectable standard which significantly differs 
from zero standard (experimentally determined).
P-values: nt: not tested, because all measured outcomes were below detection 
level.
25-plex
Inflammatory panel
GM-CSF
IL-1β
IL-1RA
IL-6
IL-8
TNF-α
Th1/Th2 panel
IFN-γ
IL-2
IL-2R
IL-4
IL-5
IL-10
Cytokine II panel
IFN-α
IL-7
IL-12p40
IL-13
IL-15
IL-17
Chemokine panel
Eotaxin
IP-10
MCP-1
MIP-1α
MIP-1β
MIG
RANTES
lowest
detectable level
(pg/ml)
11
12
50
2
7
9
3
4
30
2
2
4
10
28
4
3
6
6
3
3
3
10
10
12
10
non-involved CRPS1
     all ≤ 44 all ≤ 44
     all ≤ 48 all ≤ 48
      35940   48894  
(12665-67549) (23393-90714)
≤ 8  (≤ 8–100) 100 (≤ 8–2055)
≤ 28  (≤ 28-301) 46  (≤ 28-519)
≤ 36  (≤ 36-829) 195  (≤ 36-1923)
     all ≤ 12 all ≤ 12
     all < 16 all ≤ 16
     all ≤ 120 all ≤ 120
     all ≤ 8 all ≤ 8
     all ≤ 8 all ≤ 8
  20  (≤ 16-51) 21  (≤ 16-50)
     all ≤ 40 all ≤ 40
     all ≤ 112 all ≤ 112
325  (192-540) 386  (256-542)
     all ≤ 12 all ≤ 12
     all ≤ 24 all ≤ 24
     all ≤ 24 all ≤ 24
   29  (15-54) 24  (≤ 12-55)
  48  (24-185) 37  (≤ 12-137)
297  (126-1570) 579  (188-4415)
     all ≤ 40 all ≤ 40
199  (116-450) 290  (135-557)
     all ≤ 48 all ≤ 48
     all ≤ 40 all ≤ 40
P-value
nt
nt
< 0.001
0.001
0.006
0.013
nt
nt
nt
nt
nt
0.336
nt
nt
0.007
nt
nt
nt
0.009
0.025
0.002
nt
0.001
nt
nt
levels in blister fluid median (range) in pg/ml
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Furthermore, from the ‘chemokine panel’ IP-10 and Eotaxin were 
detectable and diminished in CRPS1, whereas from the‘Th1/Th2 
panel’ detectable amounts of IL-10 were similar in both extrem-
ities (Table 2b).
Statistical considerations
An analysis by using non-parametric statistics (Wilcoxon’s signed 
rank test), with outcomes set at the lower limit of detections in 
case of values below this limit, resulted in similar P-values for 
all parameters. We did not adjust for multiple comparison tests 
because our study had an exploratory character.
Comparison of the two methods
Levels of IL-6 and TNF-α measured by ELISA and by the 
multiplex-25 bead array assay were highly correlated (r = 0.85, 
P < 0.001 for IL-6, Figure 1a, and r = 0.88, P < 0.001 for TNF-α, 
Figure 1b).  
In the multiplex-25 bead array assay for IL-6 17 of 44 samples 
were not detectable (≤ 8 pg/ml), whereas for TNF-α 20 of 44 
samples were not detectable (≤ 36 pg/ml). In the IL-6 ELISA only 
one sample was below the detection level.
Correlations of multiplex-25 measured cytokines
The cytokines IL-6, IL-8, IL10, IL-12, TNF-α, MIP-1β and MCP-1 
were significantly correlated with each other (Table 3), whereas 
IL-12p40 was only (highly) correlated with IL-1RA (Figure 2).
Table 3: Nonparametric correlations of cytokines in blister fluid from CRPS1 
hand
P-values:  a < 0.001, b < 0.005, c < 0.01, d < 0.02, e < 0.05
IL-1RA
IL-6
IL-8
IL-10
IL-12
TNF-α
MIP-1
IL-8
0.85a
IL-10
0.56c
0.63b
IL-12
0.94a
0.51d
0.44e
TNF-α
0.78a
0.93a
0.56c
0.48e
MIP-1β
0.72a
0.76a
0.62b
0.50d
0.67b
MCP-1
0.88a
0.88a
0.59b
0.47e
0.81a
0.68e
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Figure 1: Regression curves of 44 samples of blister fluid obtained from 22 
CRPS1 patients, both from the involved and the non-involved extremity. 
Values calculated in pg/ml were plotted on logarithmic scales. Regression 
lines were calculated taking into account the left-censored values due to 
detection limits as described in the statistical methods. Dotted lines indicate 
detection levels of the multiplex-25 cytokine assay. 1a: Regression curve of 
IL-6 data from the multiplex-25 cytokine assay (Biosource) and the ELISA 
kit (Sanquin); (r = 0.85, P < 0.001). 1b: Regression curve of TNF-α data from 
the multiplex-25 cytokine assay (Biosource) and the ELISA kit (Sanquin); (r 
= 0.88, P < 0.001).
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Figure 2: Example of a regression curve between concentrations of IL-1RA 
and IL-12 in 22 blister fluid samples taken from the CRPS1 extremity (corre-
lation coefficient 0.97, P < 0.001), measured by the multiplex-25 bead array 
assay. Values are calculated in pg/ml and plotted on a logarithmic scale.
Discussion
This study investigated the involvement of inflammatory mediators 
in CRPS1 represented by a large variety of cytokines simultane-
ously measured in one small blister fluid sample. Use of the new 
multiplex-25 bead array assay allowed to determine 10 cytokines 
in blister fluid samples, considerably above the relatively high 
detection levels of these integrated cytokine assays.
Inflammatory panel
In our earlier observations of mediators in blister fluid of CRPS1 
patients (reflecting inflammation at the affected extremity), 
we decided to measure both IL-6 and TNF-α as representative 
markers of inflammation [9, 10, 19]. At that time the amounts 
of cytokines we found were within the ranges reported for other 
(mainly dermatological) diseases (Table 1). The present results 
obtained after simultaneous measurement of cytokines by the 
multiplex-25 array assay were (although 2-3 times higher) in the 
same range. In those 44 blister fluid samples high correlations 
were found between data obtained from ELISA measurements 
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and the multiplex-25 bead array assays (Figs. 1a and 1b). 
In addition to these findings, significant amounts of other (pro-) 
inflammatory cytokines were detectable in blister fluid by the 
multiplex-25 bead array assay, namely IL-8 and IL-12p40/p70. 
Furthermore, relatively high amounts of IL-1RA were found. 
Amounts of IL-1RA were comparable to those found by Blaha 
et al [20].
Using the multiplex-25 bead array assay, GM-CSF was not 
detectable. This was, however, also the case in blister fluid of 
patients with bullous pemphigus (BP), a chronic auto-immune 
blistering disease, in which GM-CSF was not detectable (< 5 pg/
ml) by ELISA [21]. 
Th1/Th2 panel
In the present study we concluded that the cytokines IFN-γ, 
IL-2, IL-2R, IL-4, IL-5 and IL-10 normally involved in the Th1/
Th2 pathways were negligible, because all calculated data were 
around or beneath the detection limits of the multiplex-25 bead 
array assay.
Detectable amounts of IL-4 and IL-10 (Table 1) and of soluble 
IL-2R have been measured in the blister fluid of patients with 
toxic epidermal necrolysis, a disease in which the early partici-
pation of activated CD8+ T lymphocytes play an important role 
[22]. 
Chemokines
Eotaxin and IL-5 are representative chemotactic cytokines to 
study the activation of skin-homed eosinophils, which in general 
represent allergic reactions [23]. In pemphigoid gestationis, a 
rare autoimmune bullous disease of late pregnancy, both markers 
are significantly increased in blister fluid [24]. In another study, 
elevated levels of both eotaxin and IL-5 in blister fluid of BP were 
found, suggesting tissue eosinophilia [25]. 
In the present study IL-5 was not detectable, although low 
detection ranges were achieved.  On the contrary, eotaxin was 
detectable at levels > 12 pg/ml blister fluid, but was surprisingly 
decreased in CRPS1 blister fluid. Therefore, we concluded that 
allergic reactions do not play an important role in CRPS1. 
In our study, both MCP-1 and MIP-1β were present in blister 
fluid in significant amounts and were increased in CRPS1 blisters 
in comparison with non-involved blister samples, suggesting an 
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ongoing involvement of activated monocytes and macrophages. 
In blisters generated in skin of chronic ambulatory peritoneal 
dialysis patients, however, MCP-1 concentrations in this inter-
stitial fluid were not related to the intensity of the inflammation 
[26, 27]. 
Source of cytokines
The involvement, cellular sources and most prominent effects 
of cytokines in BP, partly detected in blister fluids, have been 
reviewed extensively [28, 29]. In our observations, a number of 
detectable mediators measured at the CRPS1 side were correlated 
individually, except for IL-1RA, eotaxin and IP-10 (Table 4). Our 
data suggest that detectable mediators have been generated by a 
homogenous cell population. Because T-cells apparently are not 
involved, the most likely candidates are monocytes, macrophages 
and possibly fibroblasts. The main products generated by these 
cells are IL-6, IL-8, IL-10, IL-12 and TNF-α. Apparently, skin 
mast cells are also involved, as reflected by increased amounts of 
tryptase in CRPS1 blister fluid [10]. The main cytokine produced 
by mast cells is TNF-α. 
The amount of cytokines IL-8, IL-6, MCP-1, GM-CSF, TNF-α 
and MIP-1β, secreted by human epithelial cells from the female 
reproductive tract was recently assessed by Luminex bead array 
analysis [30]. The main products found were IL-8 and IL-6, but 
these were 100-fold higher than those of GM-CSF, TNF-α and 
MIP-1β. Therefore, regarding the distribution of our data, it is 
unlikely that epithelial cells contributed to the levels of cytokines 
found in blister fluid of CRPS1 patients. 
Sensitivity of multiplex-25 bead array assay
The sensitivity of multiplex bead array assays for the detection 
of soluble cytokines and the quantitative values from several 
manufacturers have been compared for serum samples [31]. Bead 
array and ELISA values appeared to be comparable between the 
manufacturers. The minimal detection range for the BioSource 
kit was comparable with the R&D Systems assay kit, but about 
2-fold and 5-fold higher than kits from Bio-Rad and LINCO 
Research, respectively. The simultaneous measurement of 15 
human cytokines (Bio-Plex system from Bio-Rad) in a single 
sample of cultured peripheral blood mononuclear cells compared 
with regular ELISA kits (purchased from a number of manufac-
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turers), resulted in high correlation coefficients ranging from 0.75 
to 0.99 [32]. Our comparison between the multiplex-25 bead array 
assay (Biosource) and ELISAs (Sanquin) for IL-6 and TNF-α also 
revealed high correlation coefficients, ranging from 0.85 to 0.88 
(Figure 1).
The high detection levels in the present study were partly caused 
by the 4-fold dilutions needed to enable separate determina-
tions by ELISA techniques. Generally, at least 50 μl will be 
recovered per blister evoked by suction. After a 2-fold dilution 
in assay matrix buffer a duplicate measurement by the multiplex 
bead array assay could be performed. Then detection levels will 
be more acceptable; however, they will still be 3-fold (or even 
more) increased compared with the commonly used ELISAs. In 
case of paired sample measurements (involved vs. non-involved) 
or treatment-affected paired sample measurements, these short-
comings are acceptable for the selected cytokine panels as demon-
strated by the results of this study.
We failed to detect substantial amounts of protein in blister fluid 
of at least 15 selected cytokines assayed in this multiplex-25 
array system, although the detection of some of these cytokines 
(such as IL-1β, IL-2, IL-5, IL-7, IL-15, IFN-γ and RANTES) has 
been realised in blister fluid using commonly available ELISA 
kits which are more sensitive [28]. Based on these ELISA derived 
data, the levels of cytokines detectable in blister fluids taken from 
a variety of diseases, generally were above our detection limits. 
Therefore, we concluded that these cytokines are not prominent 
mediators involved in CRPS1.
Conclusion
Based on our findings, routine application of a multiplex-25 bead 
array assay to detect representative cytokines in blister fluids would 
not be advisable. The use of this system is advisable for investiga-
tional purposes or for diagnosis based on selected cytokines from 
relevant literature. We therefore propose that a selection of two or 
three representatives from each panel (the inflammatory cytokines 
panel, the Th1/Th2 cytokines panel and the chemokines panel) 
would be sufficient to indicate the actvity of the CRPS1 disease. 
During the course of the disease this selected panel could also 
be used to indicate the effectiveness of therapeutic intervention. 
Based on our data and the selection made by Fahey et al [30], we 
suggest to include at least IL-6, IL-8, TNF-α, MCP-1, MIP-1β, 
104
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IL-10 and IL-12 in that investigation panel.
Future research using blister fluid should also focus on standardi-
sation of the blister techniques and the warranted inclusion of 
control samples, either from non-involved tissue or from healthy 
volunteers. 
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Abstract 
Objective: To investigate whether hypersensitivity is more 
common in CRPS1 patients than in the general population. In 
a recent study, the level of tryptase, a specific marker for mast 
cells, was significantly higher in blister fluid from the involved 
extremity of CRPS1 patients. This suggested that mast cells may 
play a role in the pathophysiology of CRPS1. Mast cells are major 
effectors in allergic reactions, and are also involved in a variety of 
non-infectious inflammatory diseases. 
Patients: Sixty-six Dutch patients with CRPS1 in one extremity 
were included. 
Outcome measures: Allergy information was obtained from the 
medical history and a modified questionnaire based on the ELON 
I study. Total IgE and allergen-specific IgE were measured from 
blood samples. Also tryptase, as a marker for mast cells, was 
measured. The data from the questionnaire were compared with 
that of the general Dutch population, and the plasma levels were 
compared to reference values and data in the literature. 
Results: The medical history did not differ from information 
provided in the questionnaire by the CRPS1-group. There was no 
significant difference between the answers to the questionnaire 
between the CRPS1 patients and the general population. The total 
IgE levels were elevated in 30% of the CRPS1 patients compared 
with 15-24% of the general population, and allergen-specific IgE 
and tryptase levels were comparable with the reference values. 
Conclusions: Based on the medical history, an allergy question-
naire, and objective laboratory findings we conclude that 
IgE-mediated hypersensitivity is not more common in CRPS1 
patients than in the general population.
Introduction 
Complex Regional Pain Syndrome type 1 (CRPS1) is a disease 
in the distal part of an extremity that usually occurs as a compli-
cation after surgery or trauma, although spontaneous occurrence 
has also been described (1). 
The pathophysiology of CRPS1 remains a matter of debate. In 
general, three mechanisms are thought to be involved: afferent 
mechanisms (e.g. neurogenic inflammation), efferent mechanisms 
(e.g. autonomic disturbances), and central nervous system mecha-
nisms (e.g. cerebral plasticity). Based on our review of the liter-
ature regarding the CRPS pathophysiology, we hypothesized that 
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after trauma or surgery, the normal sterile inflammatory response 
is exacerbated by a genetic and/or acquired immunologic disorder 
(2). Neuroimmune activation of cells in the peripheral nervous 
system, which is part of the afferent mechanism, apparently results 
in sensitization of the central nervous system, which is clinically 
displayed as allodynia and hyperalgesia (3). Neuropeptides, 
cytokines, and other mediators are released during this inflam-
mation (4,5) and cause the classical signs and symptoms, which 
resemble inflammation. These include increased skin temper-
ature, edema, pain (allodynia, hyperalgesia), loss of function, and 
redness (2,6). 
We showed that the levels of the cytonines tumor necrosis factor 
alpha (TNF-α) and interleukin-6 (IL-6) in fluid from artificially 
made skin blisters on the involved and contralateral extremities of 
patients with CRPS1 in one extremity are significantly higher in the 
involved extremity (4,7). A wide range of cells, such as activated 
T lymphocytes, monocytes, macrophages, and skin resident cells 
such as mast cells, could contribute to the production of these 
cytokines. The involvement of lymphocytes and macrophages 
is relatively difficult to determine. But the involvement of mast 
cells is relatively easy to detect by measuring tryptase, a specific 
marker for mast cells (8). 
Mast cells are major effectors in allergic reactions, and are also 
involved in a variety of non-infectious inflammatory diseases (9). 
They have many important functions, especially for innate and 
adaptive immunity, inflammation, and tissue remodelling (10). 
Mast cells are situated around dermal blood vessels (11) and are in 
close proximity to nerves in various tissues, including skin, lung 
and the intestinal mucosa (9,12,13) and a higher number of mast 
cells have been found in the distal part of extremities (11). Local 
activated mast cells release vasoactive mediators (histamine, 
leukotrienes, and prostaglandin D2) and other biologically active 
molecules (interleukins, proteases and heparin) (14) which causes 
the wheal-and-flare reaction of the skin (15,16). 
Our group measured a significantly higher level of tryptase in 
blister fluid from the involved extremity which suggested that 
mast cells may play a role in the production of cytokines such 
as TNF-α and IL-6 in CRPS1 (17). Because mast cells are also 
involved in allergic disease, the aim of the study was to inves-
tigate whether IgE-mediated hypersensitivity is more common in 
CRPS1 patients than in a reference population.
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Methods
The protocol was approved by the Medical Ethics Committee of 
the Erasmus MC, Rotterdam (MEC no. 1989.780/2001/24). All 
patients gave informed consent. The guidelines of the Decla-
ration of Helsinki (amended version of 2002) and Good Clinical 
Practice (ICH/GCP version 1996) were followed. Data collection 
and calculations were performed according to guidelines for 
registration of personal data.
Patients
Sixty-six patients with CRPS1 in one extremity, as defined by 
the diagnostic criteria of Bruehl (18) (see Table 1), were included 
in the study. These patients have participated in several studies 
performed between 2001 and 2005, either to investigate the 
pathophysiology of CRPS1 or the effects of specific treatment 
regimens (4,7,17,19). 
Registration of allergy
We obtained data on allergy through a medical history taken at 
the screenings visit to our clinic, prior to the start of medication, 
between 2001 and 2005. In 2006, all patients received a modified 
questionnaire based on the ELON I study, a Dutch arm of the 
European Community Respiratory Health Survey I (ECRHS1) 
(20,21). Questions about respiratory symptoms concerning 
asthma, nasal allergies, hay fever, and skin allergies were adopted 
from the Dutch version of the ECRHS questionnaire. 
Those who participated in the ELON 1 study are representative 
of the Dutch population in general, and were used as a control 
group. This group was divided into two age groups; a group aged 
44 years and younger, and a second group aged 45 years and older. 
The reason for this was that the first part of the ELON I study was 
conducted in the 44 years and younger age group, and the inves-
tigators wanted to also obtain information about those older than 
44 years. The CRPS1 population was also split into similar age 
groups for comparison. 
Plasma
EDTA blood samples (7 ml) were collected from the patients during 
their screenings visit to our clinic, prior to the start of medication, 
between 2001 and 2005. In 50 patients with CRPS1 in the upper 
extremity, blood was obtained by venapuncture in the involved 
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extremity and a control sample was taken from the contralateral 
extremity. In 16 patients with CRPS1 in the lower extremity, blood 
was drawn from the involved extremity, and a control sample was 
taken from the upper extremity by venapuncture. The plasma was 
isolated by centrifugation at 2650 gmax for 10 minutes at 20 °C. 
The samples were stored at -80 °C until analysis. 
Laboratory assays
Total IgE, specific IgE against a mixture of inhalant allergens 
(PhadiaTOP), specific IgE against a mixture of food allergens (fx6 
food mix), and tryptase were determined with the ImmunoCAP 
system (Phadia, Nieuwegein, Netherlands) according to the 
manufacturers’ instructions. The detection limit for total IgE was 
2 kU/l; a value of 1 kU/l was given to total serum IgE levels 
below 2 kU/l. The detection limits for specific IgE and tryptase 
were 0.35 kU/l it and 1 μg/l, respectively. The Phadia tryptase 
assay detects both α-tryptase and β-tryptase. 
The inhalant allergens mixture (Phadiatop) contained house dust 
mites, cat, horse, and dog dandruff, grass pollen mixture, mold 
mixture, tree pollen mixture, herb pollen mixture, and olive tree 
pollen. The food-allergen mixture consisted of the following 
allergen groups: chicken egg whites, cow’s milk, codfish, wheat, 
peanut, and soy.
The levels of C-reactive protein (CRP) were measured with a high-
sensitivity assay (hs-CRP) with the Immage 800 Immunochem-
istry System (Beckman Coulter, Mijdrecht, The Netherlands). 
The assay is calibrated against the CAP (College of American 
Pathologists) standard for CRPH, with a range from 0.2-1440 
mg/l. All measurements were performed in the laboratories of the 
department of clinical chemistry of the Erasmus Medical Center, 
Rotterdam, The Netherlands.
Statistical analysis
Data were analyzed with SPSS for Windows, version 14.0. For 
analysis of the questionnaire, the cross-tabs were calculated and 
the results were analyzed with the Chi-square test. A p-value ≤ 
0.05 divided by the number of comparisons (13 questions) was 
considered to indicate a significant difference (a Bonferroni 
correction). Correlation of paired samples was calculated for 
laboratory analysis using Spearman’s Rank Correlation test. A 
p-value ≤ 0.05 was considered to indicate a significant corre-
lation.
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Results
A group of 66 patients with CRPS1 in one extremity, with no 
systemic inflammation involved (normal levels of CRP in plasma), 
was included in this study. The characteristics of the patients are 
presented in Table 2.
Table 2. Characteristics of the study population.
Data are presented as median (range)
Thirty-three of the 62 patients reported an allergy in their medical 
history. No information about allergies was available for 4 patients. 
An allergy to antibiotics was reported by 24.2%, to NSAIDs 
by 9%, and for corticosteroids and calcium antagonists by 3% 
each. A skin reaction, mainly caused by plasters and metals, was 
reported by 39.4% of these patients and 6% reported an allergy to 
insect bites. An allergy caused mainly by pollen and house dust 
mites was reported by 24.2% of the patients, and a food allergy 
was reported by 6%.
The modified questionnaire was sent to the 66 CRPS1 patients, 
but 11 were not returned. No difference was found in the CRPS1 
group between the answers given on the medical history and the 
answers given on the questionnaire. Based on the Chi-square 
test, no significant difference in answers between the CRPS1 
population and the controls in both age groups was found (Table 
3).
Plasma was available from 63 of the 66 CRPS1 patients. A normal 
level of total serum IgE (<100 kU/L) was found in the plasma of 
70% of the 63 CRPS1 patients (range; 2-83 kU/L). There was 
an increase in the IgE level (>100 kU/L) in the other 30% of the 
patients (range; 109-1900 kU/L). The measurements for aller-
gen-specific IgE were performed for aeroallergens and for food 
Patient characteristic
Gender: male / female
Age in years
Duration of CRPS1, months
Location: upper / lower extremity
Side: right / left
Cause: trauma (fracture, accident) / surgery 
/ spontaneous / other
Plasma CRP: involved side / contralateral 
side (mg/l)
Value
16 / 50
50 (21 – 80) 
22 (2 – 193) 
50 / 16
34 / 32 
40 (25, 15) / 17 / 2 / 7
2.8 (0.2 – 39.4) / 2.6 (0.2 – 43.7)
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allergens. In 62 patients (94%), no IgE against food allergens 
was found (<0.35 kU/L). In 68% of the patients, no IgE against 
inhalant allergens was found (<0.35 kU/L). In the other 32% of 
patients, the levels of aeroallergen-specific IgE were elevated 
compared with the reference value of <0.35 kU/L, with a range of 
0.36-27.6 kU/L. The levels of tryptase were normal (<11.4 μg/l) 
in 91% of the patients (range; 2.0-10.2 μg/l), but were elevated in 
9% of the patients (range; 11.5-19.6 μg/l). 
Discussion 
In this study, similar answers were given on the medical history 
and on the questionnaire based on the ELON I study in the 
CRPS1 population. We also did not find any significant difference 
between the CRPS1 population and the general population. In the 
plasma of the CRPS1 patients, only a slight increase in tryptase 
was found. Total IgE was increased in 30% of the patients, but the 
levels of aeroallergen-specific IgE and food allergen-specific IgE 
were normal compared with the reference values.
Allergic asthma, allergic rhinitis (hay fever), or atopic eczema 
are frequent conditions and affect at least 20% and up to 40% 
of the adult individuals in Western societies (22-24). Allergic 
rhinitis is the most frequent condition. In recent decades, it is 
suggested that the prevalence of these conditions has increased 
(23,25). The ELON I study was performed in 1992, and our 
patients filled out the questionnaire in 2006. If the suggestion of 
increased atopy during the last decade is true, repetition of the 
ELON I study would give a higher prevalence of symptoms at the 
present time. One possibility would be that the percentages from 
the CRPS1 population would be even lower than in the general 
Dutch population instead of the same.
In the pathogenesis of allergic reaction, mast cells are involved 
in some inflammatory skin reactions (16) and in inflammatory 
reactions in CRPS1 patients (17). When mast cells are activated by 
specific antigens, surface-bound antigen-specific IgE (22,26,27) 
or stress local degranulation of the secretory granules may occur 
(28). This can cause release of vasoactive mediators and other 
biologically active molecules (14) and may induce the wheal-
and-flare reaction of the skin (15,16). This local reaction may 
play a role in CRPS1 and may cause the redness and swelling in 
the acute stage of the disease. In the plasma of CRPS1 patients, an 
increase in IL-8 was found by Schinkel et al., but no increase in 
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IL-6 was found (29). Van de Beek et al. could not find any increase 
in cytokines in the plasma of CRPS1 patients (30). However, in 
the blister fluid of patients with CRPS1, the interleukins TNF-α 
and IL-6 are increased in the involved extremity (4,31). This 
may indicate a local process with no systemic activation of these 
cells.
Tryptase is a good marker for systemic mast cell activation 
(10,27,32). Min et al. found that the levels of total tryptase are 
higher in men than in women (33). But there are several diseases, 
for example Multiple Sclerosis, which occur more often in women 
than in men and the levels of tryptase and histamine are found to 
be higher in the cerebral spinal fluid. CRPS1 also occurs more 
often in women than in men (34). Huygen et al found signifi-
cantly higher levels of tryptase in suction blister fluid from the 
involved extremity of CRPS1 patients (17), but we could not find 
significantly increased levels of tryptase in the plasma from our 
patients. This may indicate a local role for mast cells in CRPS1 
rather than a systemic one.
IgE-mediated hypersensitivity consists of two stages. The initial 
sensitization phase occurs following exposure of a predisposed 
but IgE antibody-negative individual to an allergenic substance; 
for example, house dust mites. This will lead to production of 
specific IgE antibodies. IgE circulates in the blood and binds to 
high affinity epsilon Fc-receptors on mast cells and basophils. In 
the second phase, the sensitized individual may experience any 
of a spectrum of allergy symptoms upon re-exposure to the same 
allergen. These symptoms can range from asthma, urticaria, or 
anaphylactic shock. Only 50% of those sensitized to allergens 
express these symptoms (35). IgE can be increased in all kinds of 
diseases, such as in atopy, infection, immunological disorders or 
parasitic disease, and also in people without disease. This means 
that total IgE has a very limited diagnostic value for any condition. 
It is only a good indicator of the prevalence of sensitization to 
allergens in the population and to decide if further research is 
necessary (22,27,36,37). Because of the presence of increased 
total IgE in many diseases, we measured IgE in the plasma of 
CRPS1 patients. We found an elevated level of IgE in 30% of the 
CRPS1 patients, which is higher than the 15-24% reported in the 
literature (38-40). A possible sensitization to allergens might be 
on hand, and to confirm or exclude this it is necessary to perform 
specific IgE tests to common aeroallergens and food allergens.
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Hypersensitivity to aeroallergens and food hypersensitivity are 
both based on a IgE-dependent mechanism, and mast cells and 
cytokines are the things involved in this mechanism (15) as well 
as in CRPS1 (4,17). The next research step for us in CRPS was 
to investigate whether patients with CRPS1 are hypersensitive to 
aeroallergens and food allergens. It is important to first look at 
the clinical history of the patient to diagnose hypersensitivity to 
aeroallergens and food allergens. The diagnosis can be further 
established with either skin-prick tests or measurement of specific 
IgE (23,27). The skin-prick test was not possible in the CRPS1 
population because we were no longer seeing the patients in our 
clinic. We were only able to measure the aeroallergen-specific 
and food allergen-specific IgE in the plasma we had in stock from 
this population. 
At least one positive specific IgE test to common inhalant aeroal-
lergens is seen as the golden standard for sensitization (36). 
In 32% of the general Dutch population, Kerkhof et al. found 
at least one positive allergen-specific IgE test in both men and 
women (41). This is exactly the same percentage we found in our 
CRPS1 population. This means that the level of allergen-specific 
IgE in CSPS1 patients does not deviate from the general Dutch 
population. Therefore, we conclude that CRPS1 patients do not 
have a higher prevalence of hypersensitivity to aeroallergens.
The prevalence of food hypersensitivity in adults is about 3%, and 
has increased in recent decades in the general adult population. 
But there is a large discrepancy between the self-reported preva-
lence and the confirmed prevalence by food challenge (10-14% 
vs. 3-3.2%)(15,42,43). In our population 6% reported a food 
allergy during the medical history, but a slight increase in food 
specific IgE was found in only 1 patient (1.6% of the total group). 
These percentages are lower than those in the general population, 
which means that our population does not have hypersensitivity 
to food. 
In summary, based on the medical history, an allergy questionnaire, 
and objective laboratory findings we conclude that IgE-mediated 
hypersensitivity for aeroallergens and for food allergens is not 
more common in CRPS1 patients than in the general Dutch 
population.
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General discussion
Our hypothesis was that an inflammatory process would be 
present in the initial stage of CRPS1. We based this hypothesis 
on the clinical picture of CRPS1, which presents with signs and 
symptoms resembling features of inflammation, including pain, 
heat, edema, and decreased mobility. A variety of mediators 
of inflammation could be responsible for this inflammatory 
process and subsequently cause the clinical signs and symptoms 
commonly seen in CRPS1. Furthermore, we hypothesized that 
the inflammatory process would diminish over time by normal-
ization of the mediators of inflammation. This hypothesis was 
based on changes in clinical signs and symptoms seen in CRPS1 
throughout the course of the disease.
To test our hypothesis of an inflammatory reaction in CRPS1, 
we measured proinflammatory cytokines. As the most commonly 
identified cytokines, TNF-α and IL-6 were the most likely initial 
candidates. In previous studies, these mediators were measured 
in plasma, but no differences in cytokine levels were observed 
between CRPS1 patients and controls [1, 2]. Considering the 
fact that the signs and symptoms generally present locally in an 
extremity, we concluded that the cytokines should be measured in 
a more local sample of tissue fluid. Using a suction method, we 
artificially induced skin blisters in the affected and contralateral 
extremities of study participants and measured the levels of TNF-α 
and IL-6 in the blister fluid. We found that TNF-α and IL-6 levels 
were increased in the CRPS1 side compared to the contralateral 
extremity in the first 2–3 years of the disease (Chapters 2 and 
3, Figure 1) [3, 4]. These findings are in agreement with earlier 
results found in CRPS1 patients [1, 5]. 
A remarkable finding from our work with TNF-α and IL-6 is the 
fact that about half of the patients showed no signs of an inflam-
matory process, such as increased temperature and edema [6, 7]. 
Six years after the initial event, differences in levels of TNF-α 
and IL-6 between the CRPS1 side and the contralateral extremity 
had diminished. However, some patients still showed signs and 
symptoms of inflammation [7]. Furthermore, in two other studies, 
a correlation between levels of proinflammatory cytokines and the 
disease characteristics pain, and changes in temperature, volume 
and mobility, and disease duration was lacking [6, 7]. Although 
there was a decrease of in levels of proinflammatory cytokines in 
our study, which confirms our hypothesis, the decrease did not 
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correspond with the signs and symptoms of inflammation seen in 
the CRPS1 patients. These findings contradict our hypothesis. We 
can thus conclude that TNF-α and IL-6 are involved in CRPS1 
but are most probably individually not responsible for the clinical 
features of CRPS1.
The suction method to induce blisters may in itself be a trigger for 
mediators to be released or produced in the involved (damaged) 
skin, which could explain the increased levels of cytokines in the 
CRPS1 extremity compared to the contralateral side. However, 
6 years after the initial event, the levels were similar in the 
CRPS1 side compared to the contralateral extremity. A change 
in skin structure over time might be a reason that the vacuum 
of negative pressure could not trigger the production or release 
of the mediators at that stage. Another reason for changes in the 
levels of the mediators might be changes in permeability to these 
mediators in the skin and/or the blood vessels during the course 
of the disease.
The location of the blister could have varied from the location of 
peak symptoms, a possible explanation for why we did not find 
a correlation between the levels of TNF-α and IL-6. Patients do 
not always exhibit a generalized pattern of signs and symptoms. 
Videothermography shows that patients have a patchy pattern of 
the skin temperature of the extremity, and one part of the hand or 
foot may be more affected by the disease than another part. 
A cluster analysis, as done by Bruehl et al., could possibly identify 
a clearer correlation between TNF-α and IL-6 levels and the signs 
and symptoms of CRPS1. The most likely subgroup would be 
the one that exhibits the most florid overall CRPS syndrome [8]. 
We could not perform such an analysis because the number of 
patients examined was too small.
Thus, the inflammatory mediators TNF-α and IL-6 have been 
suggested as potential contributors to CRPS1, but these proin-
flammatory cytokines do not correlate with the clinical manifes-
tations of the syndrome. For this reason, we investigated the role 
of amino acids in the pathogenesis of CRPS1, focusing especially 
on amino acids related to the NMDA receptor and nitric oxide 
synthesis. As Chapter 4 describes, relative to controls, plasma 
levels in CRPS1 patients of glutamate, arginine, taurine, and 
glycine were increased, and plasma levels of glutamine were 
decreased (Figure 1). However, the subjective measures of pain 
and indicators of psycho neuroticism and emotional instability 
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did not correlate with amino acid levels [9]. Chapter 5 reports on 
our investigation into the role of plasma 5-HT in CRPS1, which 
identified significantly elevated levels of plasma 5-HT in CRPS1 
patients compared to controls (Figure 1). Again, however, we also 
found a lack of correlation with distinct disease characteristics 
[10]. We can conclude that, like TNF-α and IL-6, the examined 
amino acids are individually not responsible for the complete 
picture of signs and symptoms of CRPS1. 
It is possible that mediators of inflammation from the categories 
of neuropeptides and eicosanoids, which we did not measure in 
this set of investigations, are elevated in CRPS1 patients. These 
mediators also can cause the pain, temperature changes, and 
edema seen in CRPS1 (Figure 1). In a previous study, increased 
levels of serum CGRP in CRPS patients were correlated with the 
incidence of nerve lesions and hyperhidrosis. There was no corre-
lation with other clinical symptoms, duration of CRPS, or pain. 
However, normalization of CGRP after therapy was accompanied 
by clinical improvement of local inflammatory signs but not by 
pain reduction [11]. In the future, it may be worthwhile to inves-
tigate whether mediators from the abovementioned categories are 
changed in CRPS1 patients and whether they correlate with the 
signs and symptoms of the disease measured in these patients. 
Based on a review of the literature on pathophysiology in CRPS 
[12], Huygen et al. hypothesized that, as the result of a genetic 
and/or acquired immunologic disorder, a normal sterile inflam-
matory response after trauma or surgical procedure becomes 
exacerbated. Secondarily, based on sensitization of the dorsal 
horn and higher centers, sensory, vasomotor, sudomotor, motor, 
and trophic changes develop, which also could be responsible for 
some of the changes in signs and symptoms during the course 
of the disease [5]. A combination of these afferent, efferent, and 
central mechanisms can demonstrate that the signs and symptoms 
seen in CRPS1 are different, as would be expected as an effect 
of an inflammatory reaction. Still, there is the issue of whether 
there is a sympathetic component together with an inflam-
matory component and whether the sympathetic nervous system 
contributes to the early inflammatory state. Furthermore, it is not 
clear whether the alterations in the central nervous system are 
primary abnormalities in CRPS1 or whether they are changes 
secondary to pain [13]. If only the afferent mechanism is activated 
in the initial stage of the disease, a correlation between the levels 
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of the proinflammatory mediators and the signs and symptoms 
would be expected. However, this has not been found in the 
studies reported in this thesis [6, 7]. 
The initial trauma could also elicit release of anti-inflammatory 
mediators, such as IL-10, which also could suppress the effects 
of the proinflammatory mediators. Such a mechanism would 
explain why the clinical features of CRPS1 are not the same in 
the different stages of the disease, as we had initially expected. 
Another possible explanation for these findings is that there 
are as-yet-unknown mediators or cells involved in the complex 
mechanism that produces the signs and symptoms of CRPS1. In 
addition, current measurement techniques may not detect these 
mediators or cells. However, we used new measurement techniques 
in the study described in Chapter 6. The use of a multiplex-25 
bead array cytokine assay and LuminexTM technology enabled 
simultaneous measurement of representative pro-inflammatory 
cytokines, Th1/Th2 distinguishing cytokines, non-specifically 
acting cytokines and chemokines. Ten representative cytokines 
were detectable; in addition to IL-6 and TNF-α, these included 
IL-1RA, IL-8, IL-12, MCP-1, and MIP-1β, all detectable and 
all increased in CRPS1 affected extremities. However, IP-10 
and eotaxin were detectable but diminished in CRPS1 [14]. In 
the future, it could be worthwhile to measure these mediators 
in blister fluid of CRPS1 patients again and correlate them with 
the signs and symptoms of the disease. One or more of these 
mediators might be responsible for the clinical manifestations of 
the disease.
We also know that these mediators are probably released from 
monocytes, macrophages and mast cells. Tryptase is a specific 
marker for mast cells and was found to be increased in blister 
fluid from the CRPS1 extremity; thus, mast cells could play a role 
in the production of cytokines in CRPS1 [5]. Mast cells are also 
known to be involved in allergic disease. Another explanation for 
the initiation or predisposition of CRPS1 could be that hypersen-
sitivity plays a role. In Chapter 7 we investigated this hypothesis 
and found that based on the medical history of the CRPS1 
patients, responses to an allergy questionnaire, and objective 
laboratory findings, such as IgE and tryptase, hypersensitivity for 
aeroallergens and food allergens is not more common in CRPS1 
patients than in the general Dutch population [15]. We conclude 
that hypersensitivity/allergic disease does not play a role in the 
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initiation or predisposition of CRPS1. In Chapter 6 we also report 
our findings, through a different approach, that allergic reactions 
do not play an important role in CRPS1.  Eotaxin and IL-5 are 
representative chemotactic cytokines for studying the activation 
of skin-homed eosinophils, which in general represent allergic 
reactions. We found that IL-5 was not detectable and eotaxin was 
surprisingly decreased in CRPS1 blister fluid.
There also might be mediators or cells that we can measure but 
that are not known to cause an inflammatory reaction with pain, 
allodynia, edema, and/or temperature changes. They could have 
their own place and function in the complex mechanism, as 
well. Finally, the mediators measured in CRPS1 patients in this 
thesis were individually not responsible for the characteristics of 
CRPS1, but a combination of these mediators might be respon-
sible for, among other things, the pain, edema, and temperature 
changes seen in CRPS1. 
Conclusion
In this thesis, we found that a variety of mediators of inflammation 
are increased in tissue fluid of CRPS1 patients. In blister fluid, 
we found increased levels of TNF-α and IL-6. These findings are 
in agreement with earlier results from studies involving CRPS1 
patients [1, 5]. In plasma, we identified increased levels of 
glutamate, arginine, taurine, glycine, and serotonin and decreased 
levels of glutamine (Figure 1). However, these individually could 
not explain the clinical signs and symptoms seen in CRPS1, which 
resemble the characteristics of inflammation, and also were not 
correlated with the duration of the disease (Chapters 2–5).
Levels of a couple of mediators are also changed in CRPS1 
patients, but whether they are responsible for the clinical manifes-
tation of the disease remains unknown (Chapter 6). Furthermore, 
IgE-mediated hypersensitivity is not an explanation for CRPS1 
(Chapter 7). We conclude that these known mediators, possibly 
also with as-yet-unknown mediators, cells and/or mechanisms, 
or a combination of these are a potential explanation for the initi-
ation, continuation and/or changes in clinical signs and symptoms 
of CRPS1 during the course of the disease.  
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Summary
Complex regional pain syndrome type 1 (CRPS1) is a disease of 
the extremity that usually occurs as a complication after surgery 
or trauma, although spontaneous occurrence has also been 
described. The prominent signs and symptoms seen in the initial 
stage of CRPS resemble the characteristics of inflammation, such 
as pain, increased temperature and color changes of the skin, 
swelling of the extremity, and loss of function. We hypothesized 
that a variety of mediators of inflammation should be present in 
the tissue fluid of patients with CRPS1 and could be responsible 
for this inflammatory process, subsequently causing the clinical 
signs and symptoms commonly seen in CRPS1. Furthermore, the 
inflammatory process would be expected to diminish over time 
by normalization of the mediators of inflammation. These ideas 
were based on the clinical signs and symptoms seen in CRPS1 
during the course of the disease.
An earlier study demonstrated that the proinflammatory cytokines 
TNF-α and IL-6 remained unchanged in plasma from CRPS1 
patients. Because of this finding and because the signs and 
symptoms present locally in an extremity, these two mediators 
were measured in a more local sample of tissue fluid. Chapter 2 
describes measurement of the levels of TNF-α and IL-6 in artifi-
cially induced blister fluid. Of the 66 CRPS1 patients assessed 
in the first 2 years of the disease, the levels were significantly 
increased on the CRPS1 side compared to the contralateral 
extremity, but only about half of the patients showed signs of 
inflammation. No correlation could be found between the cytokine 
and the characteristic pain, changes in temperature, volume and 
mobility or duration of the disease. 
Chapter 3 describes findings determined 6 years after the initial 
event, showing that TNF-α and IL-6 levels had diminished in 
the CRPS1 side of 12 patients of the original 66. However, pain, 
temperature, and volume did not change from their values at the 
initial stage, and only mobility improved after 6 years. Signs of 
inflammation were still present at this stage of the disease. Again, 
no correlation could be found between cytokine levels and the 
signs and symptoms of CRPS1 during the course of the disease. 
From the findings of these two studies, we concluded that the 
proinflammatory cytokines TNF-α and IL-6 seem to be only 
partially involved in the pathophysiology of CRPS1, as indicated 
by the lack of coherence between levels of TNF-α and IL-6 and 
the signs and symptoms of inflammation and disease duration. 
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Other inflammatory mediators, a combination of mediators, or 
even other mechanisms may, however, play a greater role in the 
pathophysiology of CRPS1 and explain in part the course of the 
disease. Amino acids, for example, could also be responsible for 
the characteristics of inflammation, as discussed in the Intro-
duction. In Chapter 4, we investigated the role of amino acids in 
the pathogenesis of CRPS1. This study shows for the first time a 
pronounced increase in plasma amino acid levels in 64 CRPS1 
patients of the initial 66. The marked differences in glutamate, 
glutamine, glycine, taurine, and arginine levels between these 
patients and 51 age- and sex-matched healthy controls suggest the 
involvement of both the endothelium-dependent arginine-nitric 
oxide system and the NDMA receptor in CRPS1. However, no 
proof could be provided that the changes in plasma amino acids 
are causally related to the pathogenesis of CRPS1. We found no 
correlations between measures of pain and indicators of psycho 
neuroticism and emotional instability. In Chapter 5, we report 
the results of an investigation of the role of serotonin (5-HT) 
with a study of 35 CRPS1 patients of the original 66 versus 35 
age-matched healthy controls. Markedly elevated plasma 5-HT 
concentrations were found, suggesting a role for 5-HT in patients 
with CRPS1. However, because of a lack of correlation between 
5-HT patterns and distinct disease characteristics, 5-HT is probably 
one of a number of mediators in the cascade of processes that 
occur in the course of this painful and debilitating disease. 
Chapter 6 describes our investigation into the involvement of 
mediators in CRPS1 by measurement of several other cytokines 
using new detection techniques that enable multiple cytokine 
measurement in small samples. With the use of new techniques, 
the multiplex-25 bead array cytokine assay and LuminexTM 
technology, 10 representative cytokines were detectable. In 
addition to TNF-α and IL-6, IL-1RA, IL-8, IL-12, MCP-1, and 
MIP-1β were detectable, and all were increased in blister fluid 
from the CRPS1-affected extremities; IP-10 and eotaxin were 
detectable and diminished in CRPS1. Multiplex bead array assays 
are useful systems to establish the involvement of cytokines in 
inflammatory processes by measurements in blister fluids of 
CRPS1. However, until now it has been unknown whether the 
newfound mediators could explain the clinical signs and symptoms 
of CRPS1.
Earlier studies showed that tryptase, a marker for mast cells, was 
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increased in CRPS1 patients. Mast cells seem to be involved in 
inflammatory reactions during CRPS1 development and could 
play a role in the production of cytokines in CRPS1. Mast cells 
are also involved in allergic reactions. Chapter 7 reports on our 
investigations of the hypothesis that allergic disease/hypersen-
sitivity could play a role in the initiation or predisposition of 
CRPS1. However, based on medical history, patient responses to 
an allergy questionnaire, and objective laboratory findings, we 
concluded that hypersensitivity was not more common in a group 
of 66 CRPS1 patients than in the general population. Our findings 
indicated that IgE-mediated hypersensitivity is not an explanation 
for the initiation of or predisposition to CRPS1.
From all the findings described in this thesis and summarized 
in Table 1, we conclude that TNF-α and IL-6 and glutamate, 
glutamine, arginine, taurine, glycine, and serotonin are partially 
involved in CRPS1 but that they are individually not responsible 
for the signs and symptoms of the disease. Other mediators, cells 
and/or mechanisms, known and unknown, likely combine with 
those described here to initiate, continue and/or elicit changes in 
the clinical signs and symptoms of CRPS1 during the course of 
the disease (General discussion).  
Table 1. Summary of the findings in this thesis
- In all stages of the disease, about half of the CRPS1 patients show signs and 
symptoms of inflammation.
- The proinflammatory cytokines TNF-α and IL-6 are increased in blister fluid 
of the CRPS1 extremity in the first 2 years of the disease. These mediators 
are not specifically responsible for the clinical features of CRPS1, which 
exhibit characteristics of inflammation. 
- Levels of TNF-α and IL-6 in blister fluid are diminished 6 years after the 
initial event. The clinical features pain, temperature, and volume are not 
improved, but mobility is. Cytokines and the disease characteristics are not 
correlated. 
- The endothelium-dependent amino acids arginine and the NMDA-receptor–
related amino acids glutamate, glutamine, and glycine are changed in plasma 
of CRPS1 patients versus healthy controls. In addition, arginine, taurine, and 
serotonin are increased in plasma of these patients. The amino acid levels are 
not correlated with clinical signs and symptoms of CRPS1.
- Patients with CRPS1 are not more hypersensitive to aeroallergens and food 
allergens than the general Dutch population. 
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Samenvatting
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Samenvatting
Complex regionaal pijn syndroom (CRPS1) is een aandoening 
van een extremiteit die gewoonlijk ontstaat na chirurgie of een 
trauma. Echter spontaan ontstaan is ook beschreven. De belan-
grijke symptomen die in de initiële fase van CRPS1 te zien zijn 
lijken op de karakteristieken van ontsteking, zoals pijn, verhoogde 
temperatuur en kleur veranderingen van de huid, zwelling van de 
extremiteit en functieverlies. Onze hypothese was dat een variatie 
van ontstekingsmediatoren aanwezig moet zijn in weefselvloe-
istof van CRPS1 patiënten. Deze mediatoren zouden verant-
woordelijk kunnen zijn voor het ontstekingsproces en als gevolg 
daarvan de symptomen kunnen veroorzaken die vaak bij CRPS1 
worden gezien. Bovendien werd verondersteld dat het ontsteking-
sproces vermindert in de loop van de tijd door normalisatie van 
de ontstekingsmediatoren. Dit was gebaseerd op veranderingen 
van klinische symtomen die gezien werden bij CRPS1 patienten 
gedurende het beloop van de ziekte.
Uit een eerdere studie is gebleken dat de pro-inflammatoire 
cytokinen TNF-α en IL-6 niet veranderd zijn in plasma van CRPS1 
patiënten. Vanwege deze bevinding en het feit dat de symptomen 
van CRPS1 lokaal in een extremiteit gezien worden, zijn deze 
twee mediatoren gemeten in lokale weefselvloeistof. Hoofdstuk 
2 beschrijft metingen van de levels van TNF-α en IL-6 in kunst-
matig gevormd blaarvocht. De levels gemeten in de eerste 2 jaar 
van de ziekte waren significant verhoogd in de CRPS1 extremiteit 
in vergelijking tot de contralaterale zijde van 66 CRPS1 patiënten. 
Slechts ongeveer de helft van de patiënten liet kenmerken van 
ontsteking zien. Er werd geen correlatie gevonden tussen de 
cytokinen en de karakteristieken pijn, temperatuur, volume, 
mobiliteit of de duur van de ziekte.
Hoofdstuk 3 beschrijft de bevindingen die gedaan zijn 6 jaar na het 
ontstaan van de ziekte. Deze laten zien dat de levels van TNF-α 
en IL-6 verminderd zijn in de CRPS1 extremiteit van 12 patiënten 
van de oorspronkelijke 66. Echter pijn, temperatuur en volume 
zijn niet veranderd. De mobiliteit is wel verbeterd na 6 jaar. 
Kenmerken van ontsteking waren nog steeds aanwezig in deze 
fase van de ziekte. Opnieuw werd er geen correlatie gevonden 
tussen de levels van de cytokinen en de symptomen van CRPS1 
gedurende het beloop van ziekte. Uit de bevindingen van deze 
twee studies kunnen we concluderen dat de pro-inflammatoire 
cytokinen TNF-α en IL-6 alleen deels betrokken lijken te zijn bij 
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de pathofysiologie. Dit vanwege het ontbreken van een correlatie 
tussen de levels van de cytokinen en de symptomen van inflam-
matie en de duur van de ziekte. Mogelijk spelen andere ontstek-
ingsmediatoren, een combinatie van mediatoren of zelfs andere 
mechanismen een grotere rol in de pathofysiologie van CRPS1 en 
kunnen deze deels het beloop van de ziekte verklaren.
Zoals besproken is in de introductie, kunnen aminozuren ook 
verantwoordelijk zijn voor de kenmerken van ontsteking. In 
Hoofdstuk 4 hebben we de rol van aminozuren in de pathogenese 
van CRPS1 onderzocht. Deze studie laat voor het eerst een 
aanzienlijke verhoging van aminozuur levels zien in 64 CRPS1 
patiënten van de oorspronkelijke 66. De duidelijke verschillen 
in levels van glutamaat, glutamine, glycine, taurine en arginine 
tussen deze patiënten en 51 gezonde controles, gematched op 
leeftijd en geslacht, suggereren de betrokkenheid van zowel het 
endotheel-afhankelijke arginine-stikstofoxide systeem als ook de 
NMDA-receptor in CRPS1. Echter, er is geen bewijs gevonden dat 
de veranderingen van aminozuren in plasma oorzakelijk gerela-
teerd zijn aan de pathogenese van CRPS1. Er is namelijk geen 
correlatie gevonden met pijn en indicatoren van psychoneurose 
en emotionele instabiliteit.  In hoofdstuk 5 zijn de resultaten 
beschreven van een onderzoek naar de rol van serotonine in 35 
CRPS1 patiënten tegenover 35 gezonde controles, gematched 
op leeftijd. Er werden duidelijk verhoogde plasma concentraties 
gevonden. Deze bevinding suggereert een rol voor 5-HT in 
patiënten met CRPS1. Echter, vanwege het ontbreken van een 
correlatie met de opvallende karakteristieken van de ziekte, is 
5-HT waarschijnlijk een van de vele mediatoren in de cascade 
van processen die voorkomen gedurende de pijnlijke en invali-
derende ziekte.
Hoofdstuk 6 beschrijft het onderzoek naar de betrokkenheid van 
mediatoren in CRPS1 door verschillende andere cytokinen te 
meten met nieuwe detectie methoden. Deze methoden maken het 
mogelijk om meerdere cytokinen te meten in een kleine hoeveelheid 
blaarvocht. Met het gebruik van deze nieuwe technieken,  the 
multiplex-25 bead array en de LuminexTM technologie, was het 
mogelijk om 10 representatieve cytokinen te detecteren. Behalve 
TNF-α en IL-6 waren ook IL-1RA, IL-8, IL-12, MCP-1 en 
MIP-1β detecteerbaar. Zij waren allemaal verhoogd in blaarvocht 
van de CRPS1 extremiteit, terwijl IP-10 en eotoxine verlaagd 
waren in CRPS1. Multiplex bead arrays zijn bruikbare systemen 
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om de betrokkenheid van cytokinen in ontstekingsprocessen vast 
te stellen door deze te meten in blaarvocht van CRPS1 patiënten. 
Het is echter tot nu toe niet bekend of de nieuwe mediatoren de 
klinische symptomen van CRPS1 kunnen verklaren.
Eerdere studies lieten zien dat tryptase, een marker voor 
mestcellen, verhoogd was in CRPS1 patiënten. Mestcellen lijken 
betrokken te zijn bij ontstekingsreacties in CRPS1 en zouden 
een rol kunnen spelen bij de productie van cytokinen bij deze 
aandoening. Mestcellen zijn tevens betrokken bij allergische 
reacties. Hoofdstuk 7 wordt het onderzoek beschreven naar de 
hypothese dat allergische aandoeningen/hypersensitiviteit  een 
rol kunnen spelen bij het ontstaan van of predispositie voor 
CRPS1. Echter, gebaseerd op de medische voorgeschiedenis, 
antwoorden op een allergie vragenlijst en objectiveerbare labora-
torium bevindingen kunnen we concluderen dat hypersensitiviteit 
niet vaker voorkomt bij de groep van 66 CRPS1 patiënten dan bij 
de algemene Nederlandse bevolking. De bevindingen indiceren 
dat Ig-E gemedieerde hypersensitiviteit geen verklaring is voor 
het ontstaan van of de predispositie voor CRPS1.
Uit alle bevindingen beschreven in deze thesis en samengevat in 
Tabel 1, concluderen we dat TNF-α en IL-6, glutamaat, glutamine, 
arginine, taurine, glycine en serotonine deels betrokken zijn 
bij CRPS1, maar deze mediatoren zijn individueel niet verant-
woordelijk voor de symptomen van de ziekte. De bekende, of 
mogelijk nog onbekende mediatoren, cellen en/of mechanismen 
of een combinatie hiervan kunnen een verklaring zijn voor het 
ontstaan, het continueren en/of het veranderen van de klinische 
symptomen van CRPS1 gedurende het beloop van de ziekte 
(General discussion). 
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Tabel 1. Samenvatting van de bevindingen in deze thesis.
- In alle fasen van de ziekte laat ongeveer de helft van de CRPS1 patienten 
kenmerken van ontsteking zien.
- De pro-inflammatoire cytokinen TNF-α and IL-6 zijn verhoogd in blaarvocht 
van de CRPS1 extremiteit in de eerste 2 jaar van de ziekte. Deze media-
toren zijn niet specifiek verantwoordelijk voor de klinische symptomen van 
CRPS1, die lijken op de karakteristieken van ontsteking.
- De levels van TNF-α and IL-6 in blaarvocht zijn verminderd 6 jaar na het 
ontstaan van de ziekte. De klinische symptomen pijn, temperatuur en volume 
zijn niet verbeterd,  mobiliteit is wel verbeterd. De cytokinen en de karakter-
istieken zijn niet gecorreleerd.
- Het endotheel afhankelijke aminozuur arginine en aan de NMDA-receptor 
gerelateerde aminozuren glutamaat, glutamine en glycine zijn veranderd in 
plasma van CRPS1 patienten in vergelijking met gezonde controles. Tevens 
zij  arginine, taurine en serotonine verhoogd in plasma van deze patienten. 
De aminozuren zijn niet gecorreleerd met de klinische symptomen van 
CRPS1.
- Patienten met CRPS1 zijn niet overgevoeliger voor inhalatie en voedsel 
allergenen dan de algemene Nederlandse bevolking.
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Ze zeggen dat het dankwoord het meest gelezen onderdeel 
van een proefschrift is...
Blijkbaar verwacht men er nogal veel van, dus voel je toch de druk 
om iets te schrijven wat iedereen leuk vindt om te lezen. Maar in 
welke vorm ga je het dan gieten, wat past het best bij mij? Moet 
ik het gewoon kort houden en het in een soort schema gieten? 
Misschien wel, maar het is minder leuk om te lezen en de kans is 
dan groot dat je iemand vergeet te bedanken. Aan de andere kant, 
veel pagina’s vol over wat iedereen voor mij betekent of betekend 
heeft, is niets voor mij. Ik hoop, en eigenlijk ga ik er een beetje 
vanuit, dat ik dit tijdens de hele periode al heb laten blijken aan 
iedereen. Dus dan moet ik toch zoeken naar een dankwoord dat 
hier tussenin zit…
Ik begin toch als eerste bij de mensen die het mogelijk hebben 
gemaakt dat ik een plek heb gekregen om mijn hele onderzoek 
te kunnen uitvoeren. Zonder het vertrouwen van professor Jan 
Klein, zonder de steun, stimulans en expertise van mijn copromo-
toren Freek Zijlstra en Frank Huygen was het niet gelukt om dit 
proefschrift te maken. Ontzettend bedankt daarvoor.
De kleine commissie bestaande uit prof. dr. D. Tibboel, prof. dr. 
H. Hooijkaas en prof. dr. W. Zuurmond wil ik hartelijk bedanken. 
Het was zeer plezierig te vernemen dat u bereid was plaats te 
nemen in de leescommissie. Daarnaast wil ik prof. dr. E. Prens en 
prof. dr. J. Danser hartelijk danken voor hun bereidheid plaats te 
nemen in de grote commissie.
Een aantal artikelen had ik niet kunnen schrijven zonder de hulp 
en expertise van een aantal andere afdelingen. Ten eerste wil ik 
Dr. Durk Fekkes en Marieke van de Heide-Mulder van de afdeling 
Neurowetenschappen en Psychiatrie bedanken voor alle hulp en 
metingen voor de artikelen over aminozuren. Daarnaast wil ik 
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dr. Albert van Toorenenbergen en dhr. Kurstjens van de afdeling 
Klinische Chemie bedanken voor hun advies en metingen met 
betrekking tot het allergie artikel. Tenslotte wil ik prof. dr. Roy 
Gerth van Wijk van de afdeling Allergologie bedanken voor zijn 
advies en het aanleveren van de allergievragenlijsten. 
Tijdens het promoveren heb ik ervaren dat het heel belangrijk is 
om fijne collega’s te hebben. Het is erg prettig als je met ze kunt 
samenwerken, discussiëren, ook gewoon kletsen en een borrel 
drinken, maar vooral dat je jezelf kunt zijn. Hiervoor wil ik vooral 
mijn “celgenoten” bedanken; Sjoerd, George, Emmy en Dirk, in 
alle opzichten bedankt voor al jullie hulp, steun, inspiratie, gezel-
ligheid, geduldigheid en enthousiasme. Claudia, hetzelfde geldt 
voor jou, bedankt voor alles en met name voor al het werk wat je 
voor mij gedaan hebt op het lab. Wilmar, jij ook bedankt, vooral 
voor het meten van de patienten. Ook natuurlijk alle andere 
studenten bedankt voor het verzamelen van patiëntgegevens in de 
loop van de jaren.
Anita heeft mij regelmatig geholpen als ik weer eens binnen kwam 
en voorzichtig begon met: „Anita…? Zou jij misschien…?” Margo 
ben ik vooral erg dankbaar voor het opzoeken en opvragen van 
alle statussen, wat een werk! Ik wil jullie en alle meiden van de 
balie, Corinne, Marion, Petra, Margreet, Marjo en Marie-Louise, 
bedanken voor het beantwoorden en uitvoeren van al mijn vragen 
en natuurlijk voor alle gezellige praatjes!
Wie ik natuurlijk niet mag vergeten is Carola. Jij vooral bedankt 
voor het aanslepen van alle kopjes thee en de daarbij behorende 
theekransjes. Het was niet voor niets…
Alle overige collega’s van het Pijnbehandelcentrum bedankt voor 
de fijne tijd op de afdeling.
Lieve Claudine en Sjoerd, ik wil jullie nogmaals laten weten dat ik 
het super fijn vind dat jullie als mijn steunpilaren willen fungeren 
tijdens het, denk ik, zwaarste moment van mijn promotie…
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 Als laatste, maar wel het meest belangrijk voor mij zijn natuurlijk 
mijn lieve en trotse ouders Gijs en Miep, mijn lieve vriend Remco 
en mijn broertje Jorrit. In het bijzonder wil ik jullie bedanken 
voor jullie hun steun en vertrouwen in alle opzichten. Lieve opa 
en oma Kampen en oma Wess, ik wil jullie bedanken voor jullie 
eeuwige vertrouwen en medeleven; “bij jou lukt het altijd”. 
Alle “Delftse” vrienden, de meiden uit Rotterdam en mijn 
vrienden uit Nijmegen; zonder alle gezelligheid, feestjes en goede 
gesprekken had ik het niet gered!!!
Jullie zijn allemaal geweldig !!!
 Dikke x
  Feik
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Feikje Wesseldijk werd geboren op 17 juli 1979 te Nijmegen. 
Het VWO examen atheneum werd behaald in 1998 aan het 
Canisius College Mater Dei te Nijmegen. Na uitgeloot te zijn 
voor geneeskunde, heeft zij in 1999 haar propedeuse Bouwkunde 
behaald aan de Technische Universiteit te Delft, om vervolgens 
dat jaar alsnog te starten met de opleiding geneeskunde aan de 
Erasmus Universiteit te Rotterdam. Zij haalde haar doctoraal 
examen in 2003 na een wetenschappelijke stage naar acupunctuur 
als behandeling voor CRPS1 op het Pijnbehandelcentrum, afdeling 
Anesthesiologie van het Erasmus MC. Na twee jaar klinische 
stage, werd in oktober 2005 het artsexamen behaald. Tijdens deze 
klinische stage werd haar gevraagd of ze opnieuw onderzoek 
zou willen komen doen op het Pijnbehandelcentrum, afdeling 
Anesthesiologie van het Erasmus MC. Daar is zij in oktober 2005 
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terie van Economische Zaken, binnen een consortium (TREND) 
voor onderzoek naar CRPS. Zij is in juli 2008 begonnen met haar 
opleiding tot anesthesioloog in het Erasmus MC.
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Mediators of inflammation in CRPS
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